Dissecting population and single-cell heterogeneity in response to anti-cancer drugs by Honarnejad, Saman
Aus dem Institut für Molekular- und Zellbiologie der Hochschule Mannheim 
(Direktor: Prof. Dr. rer. nat. Mathias Hafner) 
 
 
 
 
Dissecting population and single-cell heterogeneity 
in response to anti-cancer drugs 
 
 
 
Inauguraldissertation 
zur Erlangung des Doktor scientiarum humanarum (Dr. sc. hum.) 
der 
Medizinischen Fakultät Mannheim 
der Ruprecht-Karls-Universität 
zu 
Heidelberg 
vorgelegt von 
Saman Honarnejad 
 
aus 
Teheran, Iran 
2017
 1 
 
 2 
 
Dekan: Prof. Dr. med. Sergij Goerdt 
Referent: Prof. Dr. rer. nat. Mathias Hafner 
 
 
 
 3 
 
TABLE OF CONTENTS 
1.	 INTRODUCTION ............................................................................................. 7	
1.1	 Challenges to drug discovery and patient care .............................................. 7	
1.1.1	 High risk of failure in current drug discovery paradigm ......................... 7	
1.1.2	 Variability in patient responses to anti-cancer drugs ............................. 8	
1.1.3	 Cell-to-cell variability in responses to anti-cancer drugs ..................... 10	
1.1.4	 Aims and approaches ............................................................................... 13	
2.	 MATERIALS AND METHODS ...................................................................... 15	
1.2	 Materials ............................................................................................................ 15	
1.2.1	 Cell culture ................................................................................................. 15	
1.2.2	 Ligand and kinase inhibitors ................................................................... 15	
1.2.3	 Antibodies .................................................................................................. 16	
1.2.4	 Chemical reagents .................................................................................... 21	
1.2.4.1	 Bleaching reagents ......................................................................................... 21	
1.2.4.2	 Lysis buffer for western blot .......................................................................... 21	
1.3	 METHODS ......................................................................................................... 21	
1.3.1	 Western blot .............................................................................................. 21	
1.3.2	 ELISA .......................................................................................................... 22	
1.3.3	 High-content immunofluorescence (IF) imaging ................................... 24	
1.3.4	 Highly multiplexed cyclic immunofluorescence (CycIF) imaging ........ 27	
1.3.4.1	 CycIF image processing ................................................................................. 31	
1.3.4.2	 CycIF data analysis ......................................................................................... 32	
1.3.5	 Analysis and statistics ............................................................................. 32	
1.3.5.1	 Parameterization of dose-response curves .................................................. 32	
1.3.5.2	 Multiparametric analysis of dose-response curves ..................................... 35	
1.3.5.3	 Principal component analysis (PCA) ............................................................ 37	
1.3.5.4	 K-means clustering ......................................................................................... 37	
1.3.5.5	 viSNE (Stochastic Neighboring Embedding) ............................................... 38	
1.3.5.6	 Wanderlust ....................................................................................................... 38	
3.	 RESULTS ...................................................................................................... 39	
1.4	 Dissecting population averaged drug response ........................................... 39	
1.4.1	 Results from high-content immunofluorescence (IF) imaging and 
biochemical methods ........................................................................................... 39	
 4 
1.4.1.1	 Multiparametric analysis of dose-response curves ..................................... 39	
1.4.1.2	 Averaged signal-response parameters ......................................................... 41	
1.4.1.3	 Dynamics of MAP kinase signaling in response to EGFR inhibitors ......... 42	
1.4.1.4	 Dynamics of drug target inhibition ................................................................ 47	
1.4.1.5	 Drug combination to overcome recovery ..................................................... 50	
1.4.1.6	 Principal component analysis of drug response data ................................. 52	
1.5	 Dissecting single-cell level variability in drug response ............................. 56	
1.5.1	 Results from high-content immunofluorescence (IF) imaging ............. 56	
1.5.1.1	 Fractional analysis of signal-response curves ............................................ 56	
1.5.1.2	 Single-cell visualization of cytostatic states ................................................ 58	
1.5.2	 Results from cyclic immunofluorescence (CycIF) imaging .................. 60	
1.5.2.1	 K-means clustering in PCA space ................................................................. 60	
1.5.2.2	 viSNE visualization of drug response data .................................................. 63	
1.5.2.3	 Fractional analysis in viSNE space ............................................................... 68	
1.5.2.4	 Wanderlust visualization of steady states .................................................... 69	
4.	 DISCUSSION ................................................................................................ 72	
5.	 SUMMARY .................................................................................................... 83	
6.	 ZUSAMMENFASSUNG ................................................................................ 86	
7.	 REFERENCES .............................................................................................. 89	
8.	 APPENDIX .................................................................................................... 96	
1.6	 List of figures ................................................................................................... 96	
1.7	 List of tables ..................................................................................................... 98	
1.8	 List of equations .............................................................................................. 98	
1.9	 Publications derived from this work .............................................................. 98	
9.	 CURRICULUM VITAE ................................................................................... 99	
10.	ACKNOWLEDGMENT ................................................................................ 101	
 
 
  
 5 
LIST OF ABBREVIATIONS 
 
ng/mL                                                                                   Nanogram per mililiter 
µg/mL                                                                                   Microgram per mililiter 
µM                                                                                                          Micromolar 
mM                                                                                                            Milimolar 
M                                                                                                                     Molar 
AKT                                                                                     Protein kinase B (PKB) 
AUC                                                                                      Area Under the Curve 
CDK                                                                                 Cyclin-dependent Kinase  
CDKI                                                                   Cyclin-dependent kinase inhibitor  
CycIF                                                                            Cyclic immunofluorescence 
E50                                                                                             Half-maximal effect 
EC50                                                               Half-maximal effective concentration 
EDTA                                                                     Ethylenediaminetetraacetic acid 
EGF                                                                                    Epidermal growth factor 
EGFR                                                                   Epidermal growth factor receptor 
Emax                                                                                                   Maximal effect 
ERK                                                                Extracellular-signal-regulated kinase 
FBS                                                                                          Fatal bovine serum 
FSC                                                                                 Flow cytometry standard 
GI50                                                                          Half-maximal growth Inhibition 
H2O2                                                                                          Hydrogen peroxide 
HER2                                                    Human epidermal growth factor receptor 2 
HPLC                                                    High performance liquid chromatography 
HS                                                                                                             Hill slope 
HTS                                                                               High-throughput screening 
IC50                                                                             Half-maximal inhibitory effect 
IF                                                                                            Immunofluorescence 
KCl                                                                                             Potassium chloride 
KH2PO4                                                                         Monopotassium phosphate 
 6 
MAPK                                                                 Mitogen-activated protein kinases 
MEK                                                          Mitogen-activated protein kinase kinase 
MS                                                                                             Mass spectrometry 
mTOR                                                                    Mechanistic target of rapamycin 
Na2HPO4                                                                                 Disodium phosphate 
NaCl                                                                                               Sodium chloride 
NaOH                                                                                          Sodium hydroxide 
NMEs                                                                                   New molecular entities 
PBS                                                                                Phosphate-buffered saline 
PCA                                                                          Principal component analysis 
PCs                                                                                       Principal components 
PMSF                                                                        Phenylmethylsulfonyl fluoride 
R&D                                                                             Research and development 
ROI                                                                                              Region of interest 
SDS                                                                                    Sodium dodecyl sulfate 
STN                                                                                         Signal-to-Noise ratio 
TSCs                                                                                           Tumor stem cells 
viSNE                                                 t-distributed stochastic neighbor embedding 
 
 
 
 
 
 
 
 
 
 7 
1. INTRODUCTION 
1.1 Challenges to drug discovery and patient care 
1.1.1 High risk of failure in current drug discovery paradigm 
Drug discovery and development is costly, time consuming and extremely 
risky. Estimates suggest that it costs about $1 billion to successfully discover, 
develop and launch a single new drug in the market. About 80% of this cost 
belongs to R&D expenditure, most of which is consumed by failures at different 
stages of drug discovery and development pipeline, raising questions about 
productivity and the possible flaws in current drug discovery paradigm (Figure 
1.1) (Bains, 2004; Earm and Earm, 2014). 
 
 
 
Figure 1.1 Drug discovery and development paradigm. 
In much generalized format, a potential target for a given disease is identified 
and HTS assays are constructed to find chemical agents that modulate the target 
activity. The target is validated through secondary screens and hits are optimized 
to lead compounds by extensive medicinal chemistry programs and animal 
testing. Efficacy and safety of potential drug candidates are then evaluated in 
different phases of clinical development before approval by the regulatory 
agencies. Adapted from previously published work (Roses, 2008). 
 
Development and utilization of high-throughput screening methods has 
drastically increased the number of chemical agents entering early clinical trials. 
However, most lead compounds that progress through high-throughput screening 
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campaigns and medicinal chemistry studies fail to pass clinical trials typically due 
to lack of potency or safety (Hughes et al., 2011). It has been suggested that one 
way to avoid the high cost of failures is “quick win, fast fail” drug development 
paradigm, where technical advances in genomic and proteomic profiling methods 
as well as novel systems and quantitative modeling approaches are leveraged in 
early stages of drug development to process the potential drug candidates 
resulting in a reduced number of new molecular entities (NMEs) advancing into 
late phases of clinical trials, but those that do advance have a higher probability 
of success and launch (Paul et al., 2010). 
 
1.1.2 Variability in patient responses to anti-cancer drugs 
Over the past two decades, huge investments by large pharmaceutical 
companies has led to successful development and approval of a considerable 
number of targeted therapies for use in oncology and immune therapy (Arora and 
Scholar, 2005; Hoelder et al., 2012; Yegnasubramanian and Maitra, 2013; Zhang 
et al., 2009). In most types of cancers, patient stratification is the key to the use 
of targeted therapies, because only subsets of cancers of any type have the 
signaling dependencies that kinase inhibitors and similar drugs aim to inhibit 
(Hanahan and Weinberg, 2011). However, even in stratified patient groups a 
primary challenge facing development and use of such new medicines is patient-
to-patient variability in responses to even the most potent and targeted 
therapeutics. While the focus of classic pharmacology has been on drug-target 
interactions and structure-activity relationships, advances in affordable genomic 
sequencing of patient-derived cancer tissue biopsies has led to development of 
an entirely new branch in pharmacology called “pharmacogenomics” with the 
hope of tailored and personalized cancer care. Interestingly, patient-to-patient 
variability is also common in mechanisms of drug resistance or relapse in 
originally drug-naïve populations (Yang et al., 2010).  
A recent approach to understanding such variability involves genotyping a 
large and diverse bank (‘encyclopedia’) of patient-derived cell lines to cover the 
complex mutational landscapes within cancer types and subtypes, coupled with 
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systematic measurement of drug-response across them (Barretina et al., 2012). 
In the case of anti-cancer drugs that block cell proliferation or induce apoptosis 
(Tyson et al., 2012), cells are typically exposed to drugs over a 104 - to 105  -fold 
concentration range, and after 72–96 hours relative viability is quantitated 
typically by measuring viability surrogates such as ATP content. Such data is 
conventionally analyzed from the perspective of IC50 values (or similar 
parameters), which are descriptive of the shape of the dose-response curve at its 
midpoint. However, inspection of dose-response curves reveals that they differ 
substantially in shape from one drug to the next and from one cell line to the 
next. Thus, the focus to date on potency (Garnett et al., 2012; Heiser et al., 2012) 
ignores the potential impact and biological importance of variation in other 
parameters, such as the steepness of the dose-response curve or differences in 
maximum effect (Figure 1.2) (Fallahi-Sichani et al., 2013). 
Mutations and nongenetic factors that generate dose-response curves 
with HS < 1 and Emax > 0 are likely to be important clinically. The incremental 
therapeutic benefit of getting closer and closer to the maximum tolerated dose 
will be less for a drug with a shallow rather than steep dose-response curve. 
Studies on dose-response relationships for antiviral drugs have also concluded 
that variation in HS is important for assessing drug sensitivity and resistance. 
Attempts to identify new drugs or effective combination therapies might therefore 
focus on steepening the dose-response relationship and increasing maximum 
effect, not just decreasing IC50 (Fallahi-Sichani et al., 2013). 
 10 
 
 
Figure 1.2 Variability in shape of drug-response behavior in breast cancer 
cell line. 
Examples of response to anti-cancer drugs. Analysis of response to Docetaxel 
(anti-mitotic and microtubule stabilizing), Fascaplysin (CDK4/6 inhibitor) and 
GSK2126458 (PI3K inhibitor) implicate distinct dose response behaviors across 
55 cancer cell lines. In Docetaxel, variability can be seen clearly at the levels of 
IC50, Emax and hill slope (HS) but Fascaplysin shows most variability at the level 
of IC50 and no variability at the level of Emax or hill slope in comparison to 
GSK2126458 which shows minor variability in Emax and most variability at the 
level of HS (Fallahi-Sichani et al., 2013). 
 
 
1.1.3 Cell-to-cell variability in responses to anti-cancer drugs 
Drug action inside of a tumor rarely affects all cells in the same way, 
leaving opportunities for individual cells to escape and give rise to relapse and 
possibly resistance. While much of cell-to-cell variability in drug responses likely 
originates from genetic heterogeneity (Michor and Polyak, 2010), and existence 
of drug tolerant tumor stem cells (TSCs) (Hanahan and Weinberg, 2011), a large 
number of diverse studies have reported striking fate variability even in 
genetically identical, clonal cells in culture. Using quantitative single-cell imaging, 
fate variability has been traced to stochastic changes in protein concentrations 
that influence switching between cellular programs (Levin et al., 2011; Spencer et 
al., 2009) or variable positioning in the cell cycle (Yano et al., 2014). It is 
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therefore crucial to systematically monitor how cancer cell subpopulations 
emerge, shift or vanish from the cellular signaling landscape in response to drug 
treatment (Figure 1.3). 
To best of our knowledge, cell-to-cell variability in drug induced cell fate 
decision-making has been described primarily in compounds and ligands that 
induce apoptosis (Flusberg and Sorger, 2013; Spencer et al., 2009) but 
therapeutics that lead to induction of cytostasis have largely been unexplored. 
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Figure 1.3 Characteristics of heterogeneous and homogeneous signaling 
responses for different forms of measurements. 
(a) Schematic representations of population-level measurements of signaling and 
apoptosis over time (left) or for a dose response (right). These are expected to 
be similar whether the cells respond heterogeneously or homogeneously. Dose-
response curves can be characterized by potency (IC50), the maximal 
effectiveness (Emax), the half-point of effectiveness (E50) and the concentration at 
EC50. (b-c) Schematic representations of hypothetical results of various single-
cell end point measurements such as flow cytometry and dynamic 
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measurements for time-dependent or dose-dependent data series. Although 
these are all consistent with the hypothetical population-level measurements 
shown in a, they illustrate how population-based measurements can fail to 
distinguish between heterogeneous all-or-none signals (b) and homogeneous 
graded signals (c)(Xia et al., 2014). 
 
 
1.1.4 Aims and approaches 
Currently, the main approaches to drug discovery are phenotypic 
screening and target-based screening. The former evaluates the induced 
phenotypic effects of compounds on cells and the latter measures either the 
binding of compounds to a purified target protein or activity of the target protein in 
response to compounds (Hughes et al., 2011; Reguera et al., 2014). Historically, 
drug discovery was driven by phenotypic screening, often with limited knowledge 
of biochemical and molecular details of diseases, but more recently specially in 
cancer therapy, advances in genomics has led to identification of druggable 
target candidates in the genome, making target-centric approaches more 
popular. Conventional phenotypic assays are typically low in throughput and only 
use bulk measurements of population average to examine drug responses. 
Target-based approaches are high in throughput but lack physiological 
environments to probe compound pharmacodynamics in the cellular context. 
Indeed, it has been argued that too much focus on genetic approaches to 
validate targets for use in target-based drug discovery has resulted in reduced 
success in discovering first-in-class medicines (Hoelder et al., 2012; Samsdodd, 
2005). 
Understanding the mechanisms of action of therapeutic drugs requires 
characterization of drug-induced changes in intracellular state. In the case of 
targeted anti-cancer drugs these typically involve inhibition of oncogene 
signaling, changes in cell cycle distribution and induction of senescence or 
apoptosis. Multiplex methods are required to monitor this diversity and the 
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methods described in this thesis illustrate that microscopy is ideal for this 
purpose. We argue that cell-based measurements of target and close-to-target 
protein states (phospho-states) and abundance with automated multiplexed high-
content and high-throughput microscopy methods, not only combines the 
advantages of both phenotypic and target-based approaches (in the case of 
engineered cell lines), but also allows assessment of single-cell drug responses. 
Single-cell profiling uncovers relationships between target inhibition and induction 
of cellular phenotypes that are obscured by population average methods and it 
fits well into the workflow of drug discovery. It can also be very economical with 
respect to reagents and numbers of cells (an important consideration with 
patient-derived materials). To this end, we propose utilization of an automated 
high-content immunofluorescence (IF) combined with a novel highly multiplexed 
cyclic immunofluorescence (CycIF) single-cell imaging method instead of 
conventional HTS techniques that only use bulk measurements of population 
average to address issues of potency and efficacy of chemical agents early in 
preclinical studies with an emphasis on single-cell pharmacodynamics. 
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2. MATERIALS AND METHODS 
1.2 Materials 
1.2.1 Cell culture 
MCF10A, BT474, SkBr3, hMEC, H1666, H1650 and H3255 cell lines were 
obtained directly from the American Type Culture Collection (ATCC), 21PT and 
21MT1 cells were obtained from Gray lab and HMLE and HMLER cells were 
obtained from Weinberg lab. MCF10A, 21PT and 21MT1 cell lines were cultured 
under conventional conditions in DMEM/F12 (Invitrogen) supplemented with 5% 
(v/v) horse serum, EGF (20 ng/ml), insulin (10 µg/ml), hydrocortisone (0.5 µg/ml), 
and cholera toxin (100 ng/ml) with penicillin (50 U/ml) and streptomycin (50 
µg/ml) and beside BT474 cell line that was grown in RPMI media supplemented 
with 10% (v/v) FBS and penicillin (50 U/ml) and streptomycin (50 µg/ml), the rest 
of the cell lines were cultured according to ATCC culture methods. 
1.2.2 Ligand and kinase inhibitors 
EGF ligand was purchased from PeproTech (Cat. No. AF-100-15) and the 
small molecule drugs Dactolisib (NVP-BEZ235), Torkinib (PP242), Gefitinib, 
Erlotinib, MK2206, Triciribine, Selumetinib (AZD6244) and PD0325901 were 
purchased from Selleck Chemicals and Lapatinib from LC laboratories. All 
compounds were dissolved in DMSO as 10 mM stock solutions. For drug dose-
response, ~5,000 cells for MCF10a, 21PT and 21MT1 cells or ~15,000 cells for 
the rest of the cell lines were plated per well in two replicate 96-well plates 
(Corning) in full growth media for 24 hours and then either starved over night and 
treated with EGF or in full serum treated with drugs for 24-48 h. For perturbations 
and their nominal targets see Figure 2.1. 
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Figure 2.1 Nominal targets of ligand and kinase inhibitor panel. 
Epidermal growth factor (EGF) binds to the extracellular domain of epidermal 
growth factor receptor (EGFR) causing homo- (with itself) or hetero- (with other 
receptors like human epidermal growth factor receptor 2) dimerization and 
autophosphorylation of the kinase domain. This activity leads to binding to 
downstream adaptor proteins and activation of MAPK and PI3K/AKT signaling 
pathways. Erlotinib, Gefitinib and Lapatinib compete with ATP and inhibit the 
kinase activity of EGFR. Lapatinib is a dual kinase inhibitor and in addition to 
EGFR it also inhibits the kinase activity of HER2 (human epidermal growth factor 
receptor 2). PD0325901 and Selumetinib (AZD6244) inhibit MAPK signaling by 
targeting MEK. Triciricbine and MK2206 inhibit different subunits of AKT. Torkinib 
(PP242) is an mTOR targeting drug and Dactolisib is a dual inhibitor of PI3K and 
mTOR. 
 
 
1.2.3 Antibodies 
Antibody validation is not a straightforward process and we typically rely 
on commercial antibodies already in wide spread use. In studies of cell signaling, 
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antibody selectivity in a particular cell type is assessed using activating 
extracellular ligands in combination with kinase inhibitors. In principle many 
primary antibodies that work for use in biochemical methods such as western 
blotting, do not work well for immunofluorescence. One reason for this issue is 
that in western blotting, proteins are fully denatured after being exposed to 
detergents likes SDS but in immunofluorescence, antibodies might not reach 
their specific epitopes due to protein folding that remains intact after fixation. 
For the purpose of testing and validating relevant antibodies for the targets 
of interest in this study, MCF10a cells were starved overnight and exposed to 
EGF at 8 doses in serum-free media for 24 hours. Conventional four-color 
immunofluorescence was used to characterize cells stained with the DNA dye 
Hoechst 33342 to label nuclei and one of the 30 different primary antibodies 
(Figure 2.2). 
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Figure 2.2 Antibodies tested for immunofluorescence imaging. 
Antibodies specific to total or phosphorylated levels of different proteins that 
regulate signaling pathways such as those controlling MAPK, AKT or 
translational control as well as those specific to cell cycle regulation were probed 
by measuring their dynamic range in response to increasing doses of EGF. 
 
From the tested antibodies, 20 markers showed acceptable STN ratio and 
we used these antibodies for drug screen using conventional 
immunofluorescence imaging (Figure 2.3). 
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Figure 2.3 Antibodies used for high-content immunofluorescence imaging 
and drug screening. 
Antibodies specific to total or phosphorylated levels of different proteins that 
regulate signaling pathways such as those controlling MAPK, AKT or 
translational control as well as those specific to cell cycle regulation were used in 
drug screen using conventional immunofluorescence imaging. 
 
 
 
For the purpose of testing and validating relevant antibodies to for the 
targets of interest to be used in CycIF method, MCF10a cells were either starved 
for 24 hours and then treated with EGF at different concentrations or exposed to 
one of the four kinase inhibitors (denoted in Figure 2.1 with a star) in full serum 
and then subjected to CycIF staining (Figure 2.4). 20-channel images were 
registered against nuclei to align images from successive cycles, segmented and 
single-cell features were extracted using ImageJ software (Abràmoff et al., 2004) 
corresponding to whole cell, membrane, cytoplasmic and nuclear intensities. 
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Figure 2.4 Antibodies used for cyclic immunofluorescence (CycIF) ligand 
response and drug screen. 
Antibodies specific to total or phosphorylated levels of different proteins that 
regulate signaling pathways such as those controlling MAPK, AKT, NFkB, 
apoptosis or translational control as well as those specific to cell differentiation, 
cytoskeleton and cell cycle regulation were used for EGF ligand and drug 
screening using CycIF. 
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1.2.4 Chemical reagents 
1.2.4.1 Bleaching reagents 
140 µl of fluorophore inactivation solution containing 3% H2O2 and 20 mM 
NaOH in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 1.8 mM 
KH2PO4; pH ≈ 9.5) was added to each well and the samples were continuously 
illuminated with an ordinary incandescent table lamp. Fluorophore inactivation 
was monitored using a Cytell Imaging system in continued presence of the 
oxidation solution. When inactivation was complete (typically 60 min) cells were 
washed three times with 250 µl PBS using BioTek EL406 plate washer and then 
incubated with Odyssey Blocking Buffer (OBB) for an hour. After blocking, 
samples were subjected to the next round of staining, as described above. H2O2 
was obtained as a 30% solution from Sigma (Cat. No. H1009), NaOH as pellets 
(Cat. No. S5881), and hydrochloric acid as a 37% (12 M) solution (Cat. No. 
258148) (Lin et al., 2015). 
 
1.2.4.2 Lysis buffer for western blot 
1% Triton lysis buffer was prepared by adding 1 mL of Triton X-100 (10%) 
to 9 mL of PBS. 1 pellet of mini complete protease inhibitor (1 tablet per 10 mL) 
was added to the solution with 10 mM final EDTA concentration. 20 mM BME 
was added to the final solution. 
 
1.3 METHODS 
1.3.1 Western blot 
Cells were seeded in 6-well plates and treated with Lapatinib the next day. 
At desired time points, the media was aspirated and cells were washed with 1 mL 
of ice cold PBS. PBS was aspirated completely and 150 µL of ice-cold Triton 
lysis buffer was added to the wells. The plates were left on ice for 20 mins and 
scraped occasionally. The lysates were collected from the wells and transferred 
to eppendorf tubes. Tubes were spun at maximum speed for 10 mins in cold 
 22 
room. The lysates were removed from the nuclear pellet, added to new tubes and 
normalized using Bradford assay. The normalized sample lysates were added to 
tubes containing (5x) standard buffer (SB), boiled for 1 min and stored at -80°C. 
Lysates were fed into precast gels and ran in 1x SDS running buffer. Gels 
were transferred in transfer buffer to membranes pre soaked in 100% methanol 
over night in cold room. The next day membranes were blocked with Odyssey 
Blocking Buffer for 1 hour at room temperature with gentle shaking. Blocking 
buffer was aspirated and primary antibodies were added to the membranes 
according to vendor’s recommended dilution for western blot application in 
Odyssey Blocking Buffer plus 0.1% Tween-20 and incubated for 2 hours at room 
temperature with gentle shaking. Membranes were washed 5 times for 5 mins 
each round with generous amounts of PBS plus 0.1% Tween-20 with gentle 
shaking. Secondary IRDye antibodies were diluted (1:20,000) in Odyssey 
Blocking Buffer plus 0.1% Tween-20 and incubated with the membranes for 1 
hour with gentle shaking and protected from light. Membranes were washed 5 
times for 5 mins each round with generous amounts of PBS plus 0.1% Tween-20 
with gentle shaking. Finally, membranes were soaked in 1x PBS and scanned on 
Odyssey Infrared imaging system. 
1.3.2 ELISA 
Lysis buffer was prepared immediately before use and kept on ice at all 
times.150-200 µl/well was used in 6-well plate. IC Diluent #12 (dilute Sample 
Diluent Concentrate 2x diluted with an equal volume of water) + 1:140 aprotinin + 
1:1000 LPC + 1:100 Thermo Halt phosphatase inhibitor cocktail + 1:500 PMSF 
(500 mM stock) IC Diluent #12 = 1% NP-40, 20 mM Tris (pH 8.0), 137 mM NaCl, 
10% glycerol, 2 mM EDTA, 1 mM activated sodium orthovanadate. Plates were 
put on ice and quickly washed with ice-cold PBS. PBS was aspirated and the 
lysis buffer was added. Cells were scraped off the plates and put in eppendorf 
tubes. They were kept on ice during this time and rocked gently on ice for 30 
minutes at 4°C. Then microcentrifuged at 14,000 g for 5 minutes at 4°C and the 
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supernatant was slowly transferred into clean eppendorf tubes, making sure 
sample is well mixed and aliquotted if needed and stored at -80°C. 
Capture antibody was reconstituted if needed and then vortexed. 
Appropriate amount of diluted capture antibody was prepared in PBS without 
carrier protein.  Immediately 100 µl was pipetted into each desired well. Plates 
were sealed and incubated overnight at room temperature and gently agitated on 
rocker. The final concentrations of the used capture antibodies were 0.4 µg/ml for 
EGFR and 7 µg/ml for HER2. Blocking solution was brought to room temperature 
to be used. Capture antibody was aspirated followed by washing four times with 
400 µl/well 1x PBS-T (0.05% Tween-20 in PBS) and once with 1x PBS. Wash 
buffer was gently agitated for 0.5 – 2 min before removing.  After the last wash, 
plates were inverted on clean paper towel and aspirated. 300 µl/well of blocking 
solution was pipetted followed by incubation at room temperature with gentle 
agitation for 1-2 hours. 2 ug/well primary antibody for p-EGFR, 40 µg/well for p-
HER2 was pipetted. The blocking buffer was aspirated followed by washing four 
times with 400 µl/well 1x PBS-T (three times for the total protein assays) and 
once with 1x PBS. After the last wash, plates were inverted on clean paper towel 
and aspirated. 100 µl/well of the samples were added in IC Diluent #12. Plates 
were seal and incubated for 2 hours at room temperature on rotator. Standards 
and samples were aspirated, followed by washing four times with 400 µl/well 1x 
PBS-T (three times for the total protein assays) and once with 1x PBS. Detection 
antibody (p-EGFR and p-HER2 at 1:200 dilution) was prepared in IC Diluent #14 
and 100 µl/well was pipetted. Plates were sealed and incubated overnight at 4°C 
with continued rocking. The next day, wells were washed four times with 400 
µl/well of 1x PBS-T and once with 1x PBS. After the last wash, plates were 
inverted on clean paper towel and aspirated. Donkey anti-Rabbit HRP-
conjugated antibody in IC Diluent #14 (p-EGFR = 1:40,000, p-HER2 = 1:5,000) 
was prepared and 100 µl/well pipetted. Plates were sealed and incubated for 2 
hours at room temperature rocking. Substrate solution was warmed to room 
temperature before use. Plates were washed four times with 400 µl/well 1x PBS-
T and once with 1x PBS, followed by gentle agitation of wash buffer for 1-2 min 
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before removing. After the last wash, plates were inverted on clean paper towel 
and aspirated. 100 µl/well substrate solution was added (1:1 Substrate Reagents 
A & B; mixed together within 15 minutes of use and protect from light) to wells. 
After 20 minutes incubation at room temperature, 50 µl/well stop solution was 
added to wells followed by pipetting up and down to mix and samples were 
quantified using a plate reader (Kleiman et al., 2011). 
1.3.3 High-content immunofluorescence (IF) imaging 
Cells were fixed in 2% paraformaldehyde for 10 min at room temperature 
and washed with PBS-T (0.1% Tween-20, Sigma-Aldrich), permeabilized in 
methanol for 10 min at room temperature, washed with PBS-T, and blocked in 
Odyssey Blocking Buffer (OBB, LI-COR Biosciences) for 1 hour at room 
temperature. Cells were incubated overnight at 4°C with primary monoclonal 
antibodies from rabbit, goat, or mouse in OBB (Figure 2.3, Table 1 for more 
details). Cells were washed three times in PBS-T and incubated with fluor-
conjugated secondary antibodies against rabbit, goat, or mouse IgG diluted 
1:2,000 in OBB (Table 2). Cells were washed once in PBS-T, once in PBS and 
incubated in 250 ng/ml Hoechst 33342 (Invitrogen) and 1:500 Whole Cell Stain 
Blue (Thermo Scientific) solutions. Cells were then washed twice with PBS and 
imaged with a 10x objective on Operetta automated epifluorescence microscope 
(PerkinElmer) (Table 3). Automated image segmentation and single-cell 
quantification of stain intensities was performed using standard routines 
implemented in Columbus and Harmony (PerkinElmer, Figure 2.5). For 
illustration purposes, representative images were RGB-transformed and merged 
using ImageJ (Abràmoff et al., 2004). 
  
 25 
 
Table 1 List of primary antibodies for ligand and drug response. 
Host Antibody Target residue Dilution Vendor 
Rabbit phospho-RSK Ser-380 1:200 GeneTex 
Rabbit Phosphor-
ERK1/2 
Thr202/Tyr204 1:400 Cell Signaling 
Rabbit phospho-Akt Ser473 1:400 Cell Signaling 
Rabbit Foxo3a Total 1:400 Cell Signaling 
Rabbit phospho-S6 Ser235/236 1:400 Cell Signaling 
Rabbit phospho-4E-
BP1 
Thr37/46 1:400 Cell Signaling 
Rabbit phospho-CDK2 Tyr15 1:400 GeneTex 
Rabbit phospho-CDC2 Tyr15 1:200 Cell Signaling 
Rabbit phospho-
p57Kip2 
Thr310 1:200 Cell Signaling 
Rabbit phospho-
p27Kip1 
Ser10 1:200 GeneTex 
Rabbit phospho-
p27Kip1 
Thr187 1:200 Santa Cruz 
Rabbit Survivin Total 1:800 Cell Signaling 
Rabbit p27kip1 Total 1:200 Cell Signaling 
Rabbit p21Cip1 Total 1:400 Cell Signaling 
Rabbit P57Kip2 Total 1:200 Cell Signaling 
Rabbit FoxM1 Total 1:400 Cell Signaling 
Rabbit Cyclin A Total 1:200 Santa Cruz 
Rabbit Cyclin B1 Total 1:400 Cell Signaling 
Goat phospho-Rb Ser807/811 1:400 Santa Cruz 
Mouse p27Kip1 Total 1:200 Becton 
Dickenson 
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Figure 2.5 High-content/high-throughput IF and CycIF imaging pipeline. 
Multi-well plates with cells that were perturbed with increasing doses of different 
drugs are fixed at desired time points and stained with a DNA dye and primary 
and then secondary antibodies for IF pipeline or alternatively with primary 
antibodies conjugated with alexa-fluor dyes for CycIF pipeline. Plates are 
scanned on an automated high-throughput epifluorescence microscope and 
images are segmented for IF or registered after each round of staining and 
segmented for CycIF. Single-cell features from different cellular compartments 
are generated and multiplexed high-dimensional data from mean and single-cell 
dose response curves are used for statistical analysis and high-dimensional 
visualization. 
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Table 2 List of secondary antibodies for ligand and drug response. 
Host Dye Dilution Vendor 
Donkey Alexa-647 1:2000 Invitrogen 
Donkey Alexa-488 1:2000 Invitrogen 
Donkey Alexa-568 1:2000 Invitrogen 
 
Table 3 List of filters used for IF imaging. 
Filter Wavelength 
Excitation 360-400 
Excitation 460-490 
Excitation 560-580 
Excitation 620-640 
Emission 410-480 
Emission 500-550 
Emission 590-640 
Emission 650-700 
 
1.3.4 Highly multiplexed cyclic immunofluorescence (CycIF) 
imaging 
Cells were fixed in 4% paraformaldehyde for 30 min at room temperature 
and washed three times with PBS, permeabilized in ice-cold methanol for 10 min 
at room temperature, rewashed with PBS, and blocked in Odyssey blocking 
buffer (LI-COR) for 1 hour at room temperature. Cells were incubated overnight 
at 4°C with primary antibodies in blocking buffer. For staining with fluorophore-
conjugated primary antibodies, cells were washed three times with PBS and 
stained with Hoechst 33342 (0.1 µg/ml) for 15 min at room temperature. For 
primary antibodies that were not fluorophore-conjugated (i.e. for indirect 
immunofluorescence), cells were washed three times with PBS, incubated with 
fluorophore-conjugated secondary antibodies in blocking buffer for 1 hour at 
 28 
room temperature, washed with PBS and then stained with Hoechst 33342 for 15 
min at room temperature. After image acquisition, cells were washed three times 
with PBS (250 µl per well) using BioTek EL406 plate washer with final aspiration 
so as to empty each well. 100 µl of a mixture of 3% H2O2 and 20 mM NaOH in 
PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 1.8 mM KH2PO4) (pH ≈ 
9.5) were added to each well for 1 hour at room temperature and continuously 
illuminated with an ordinary incandescent table lamp. To monitor for fluorophore 
inactivation, remaining fluorescence was measured on a microscope prior to 
removal of the oxidation solution. Cells were then washed three times with 250 µl 
PBS using a plate washer and reincubated with blocking buffer. After blocking, 
samples were subjected to the next round of staining, as described above. H2O2 
was obtained as a 30% solution from Sigma (Cat. No. H1009), NaOH as pellets 
(Cat. No. S5881), and hydrochloric acid as a 37% (12 M) solution (Cat. No. 
258148) (Lin et al., 2015). 
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Figure 2.6 CycIF imaging method variants. 
(a) An overview of the CycIF procedure. Four-color staining alternates with 
fluorophore inactivation by oxidation to progressively build a multichannel image. 
(b) CycIF procedure using direct immunofluorescence (with fluorophore-
conjugated antibodies) and chemical inactivation of fluorophores. COLO858 
melanoma cells were fixed and stained using antibodies for Ki-67 (Alexa 488), p-
Histone H3 (Alexa 555), p21/Cip1 (Alexa 647) and Hoechst (left panel). Cells 
were exposed to fluorophore-inactivation by oxidation using hydrogen peroxide, 
high pH and light and then reimaged (middle panel) to confirm efficient bleaching. 
Cells were then stained with fluorophore-conjugated antibodies for p-S6S240/244 
(Alexa 488), p-RbS807/811 (Alexa 555), p-S6S235/236 (Alexa 647) and Hoechst. (c) 
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CycIF procedure using indirect immunofluorescence and protease-mediated 
antibody stripping. MCF7 cells were fixed and stained using primary antibodies 
for p-ERK1/2T202/Y204 (rabbit), p53 (mouse), Alexa 488-conjugated anti-rabbit, and 
Alexa 647-conjugated anti-mouse secondary antibodies (left panel). Cells were 
digested with pepsin/papain mixture and reimaged (middle panel). Cells were 
restained using primary antibodies for p-RbS807/811 (rabbit), p-Histone H2A.XS139 
(mouse), Alexa 488-conjugated anti-rabbit, and Alexa 647 conjugated anti-mouse 
secondary antibodies (right panel) (Lin et al., 2015). 
 
Table 4 List of conjugated antibodies used in CycIF. 
 Alexa-488/FITC Alexa-555/Cy3 Alexa-647/Cy5 
Cycle 
1 
p53 Antibody (DO-1, sc-126) 
Dilution 1:400 
ActinRed 555 
(Invitrogen #R371112, Lot 
#1646656) 
FoxO3a (75D8) 
Rabbit mAb 
(CST #2497, Lot 
#10) Dilution 
1:400 
Cycle 
2 
p-ERK1/2 T202/Y204  
(CST #4344, Lot #12) Dilution: 
1:200  
p-Rb S807/S811  
(CST #8957, Lot #1) 
Dilution: 1:400 
p21 Waf1/Cip1  
(CST #8587, Lot 
#3) Dilution: 
1:200 
Cycle 
3 
Cyclin D1  
(AB #AB190194, Lot 
#GR199456-1) Dilution: 1:400 
p-AuroraABC  
(CST #13464, Lot #1) 
Dilution: 1:200 
p27  
(AB #AB194234, 
Lot #GR200274-
1) Dilution: 1:400 
Cycle 
4 
p-S6 S240/S244  
(CST #5018, Lot #4) Dilution: 
1:800 
p-Histone H3 S10  
(CST #3475, Lot #2) 
Dilution: 1:800 
p-S6 S235/S236  
(CST #4851, Lot 
#22) Dilution: 
1:400 
Cycle 
5 
Bax  
(BIO #633603, Lot #B169774) 
Dilution: 1:400 
S6 (CST #6989, Lot #2) 
Dilution: 1:200  
p-H2.AX S139  
(BIO #613407, 
Lot #B199199) 
Dilution: 1:400 
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Cycle 
6 
PCNA  
(CST #8580, Lot #1) Dilution: 
1:400 
pan-Keratin  
(CST #3478, Lot #4) 
Dilution: 1:200 
pan-Akt  
(CST #5186, Lot 
#3) Dilution: 
1:400 
Cycle 
7 
EGFR  
(CST #5616, Lot #4) Dilution: 
1:400 
VEGFR2  
(CST #12872, Lot #1) 
Dilution: 1:400 
mTOR  
(CST #5048, Lot 
#2) Dilution: 
1:300 
Cycle 
8 
E-Cadherin  
(CST #3199, Lot #11) Dilution: 
1:200 
β-Actin  
(CST #8046, Lot #1) 
Dilution: 1:200 
Vimentin  
(CST #9856, Lot 
#7) Dilution: 
1:800 
Cycle 
9 
Ki-67  
(CST #11882, Lot #4) Dilution: 
1:400 
cPARP  
(CST #6894, Lot #1) 
Dilution: 1:200 
p65 NFkB  
(AB #AB190589, 
Lot #GR199457-
1) Dilution: 1:800 
 
1.3.4.1 CycIF image processing 
Plates were imaged with 10x objective using a Cytell Cell Imaging System 
(GE). All raw images are available on HMS-LINCS webpage 
(http://lincs.hms.harvard.edu/). Image segmentation and analysis were performed 
using ImageJ. Hoechst images were converted to nuclear masks and ROIs.  The 
same ROIs were applied to images for all data channels (488/555/647) and the 
fluorescent intensities were obtained.  The nuclear masks were then converted 
into RING ROIs outside the nuclei and used to quantify channels of interest.  The 
intensity data generated by ImageJ were then passed to MATLAB for further 
processing and analysis. 
For sequential imaging of CycIF, image registration was accomplished 
using ImageJ software package scripts and the provided plugins (StackReg: 
http://bigwww.epfl.ch/thevenaz/stackreg/; MultiStackReg: 
http://bradbusse.net/downloads.html). Hoechst images from different cycles were 
inputted as reference images to generate registration information. The same 
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registration information was used to transform images from other channels.  The 
transformed images were compiled into multi-image stacks and the image 
segmentation and data retrieval were performed as described above. All ImageJ 
and MATLAB scripts are available on this website 
(http://lincs.hms.harvard.edu/lin-NatCommun-2015/). 
1.3.4.2 CycIF data analysis 
The viSNE and Wanderlust Matlab codes in the CYT package were 
obtained from the Pe’er lab webpage 
(http://www.c2b2.columbia.edu/danapeerlab/html/software.html). The raw data 
generated from CycIF was imported into FlowJo and converted to FCS files. FCS 
files were then used as input for both the viSNE and Wanderlust toolkits. All data 
files were aggregated and used to generate viSNE diagrams. For Wanderlust, 
the same FCS files were normalized using the Wanderlust script with default 
parameters (L number = 30; K number = 5; Number of landmarks = 20; Number 
of graphs = 25; Distance Metric = Cosine). Data from the DMSO-treated control 
sample were the starting point for the Wanderlust trajectory. 
1.3.5 Analysis and statistics 
1.3.5.1 Parameterization of dose-response curves 
Variability in shape of dose-response curves can be quantified by 
performing a multiparametric analysis using a conventional logistical sigmoidal 
function  
 
Equation 1 
𝑦 = 𝐸!"# + 𝐸! − 𝐸!"#1+ 𝐷𝐸𝐶!" !"  
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where y is a response measure at dose D (typically the experimental data), E0 
and Einf are the top and bottom asymptotes of the response, EC50 is the 
concentration at half-maximal effect, and Hill slope (HS) is a slope parameter 
analogous to the Hill coefficient. Three values derived from equation 1 are in 
common use: IC50, Emax and the area under the dose-response curve (AUC). 
Although they are not strictly parameters of equation 1, we refer to IC50, Emax and 
AUC as ‘parameters’ for simplicity. EC50 and IC50 are the classic measures of 
drug potency, and Emax and Einf are measures of drug efficacy (for anticancer 
drugs, Emax varies between 1 at low doses and 0 at high doses, which 
corresponds to the maximum response of the cells). AUC combines potency and 
efficacy of a drug into a single parameter. AUC values can be compared for a 
single drug across multiple cell lines exposed to the same range of drug 
concentrations, but comparison of different drugs is problematic (because the 
scaling between drugs and dose ranges is generally arbitrary). In the simple case 
of second-order competitive inhibition, the case considered in most 
pharmacology textbooks, E0 = 1, Emax = Einf = 0, EC50 = IC50 and HS = 1 (Figure 
2.7). 
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Figure 2.7 Parameterization of dose-response curves. 
Schematic of key dose-response parameters (EC50, IC50, Einf, Emax and AUC) 
calculated following curve fitting to the cell survival data. The pink area 
represents the AUC. The red dashed line represents the simple case of E0 = 1, 
Emax = Einf = 0, EC50 = IC50 and HS = 1. Effects of variations in EC50, hill slope 
(HS) and Einf on the shape of dose-response curve are shown on the right. 
Details of parameters and logistic equation are described in the text (Fallahi-
Sichani et al., 2013). 
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Figure 2.8 Growth inhibition curves. 
Schematic of key dose-response parameters. Half-maximal growth inhibition 
(GI50) and total growth inhibition (TGI) that can be calculated by fitting logistic 
curves to data on relative cell growth comprising a change in cell number after 
drug treatment normalized to the change in cell number in an untreated control 
well (Fallahi-Sichani et al., 2013). 
 
1.3.5.2 Multiparametric analysis of dose-response curves 
Methodologies for multiparametric analysis of dose response curves were 
adopted from previously published work (Fallahi-Sichani et al., 2013) that used 
previously published data comprising CellTiter-Glo measurement of per-well ATP 
concentrations (a metric of metabolically active cells) for 64 anti-cancer drugs 
and 53 well-characterized breast cell lines (Heiser et al., 2012). In this dataset, 
assays were performed before and 3 days after exposure to drugs at nine doses 
spanning a ~105-fold range (with maximum doses between 0.5 µM and 20 mM 
depending on potency. We computed viability as y = N/NC, where the cell number 
N was measured in the presence of drug, and cell number NC is measured in a 
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not available) (Barretina et al., 2012). Multiparametric analysis yielded values for 
EC50, IC50, GI50, HS, Einf, Emax and AUC for 2,789 drug–cell line combinations; 
data filtering described in the text and revealed substantial differences from one 
drug and cell line to the next (Figure 2.8). 
 
Figure 2.9 Parameters derived from drug response measured by relative 
ATP content. 
The range of dose-response parameters, IC50 (a measure of potency), Emax (a 
measure of efficacy) and HS (a measure of curve steepness) estimated for 64 
compounds across 53 of the breast cell lines are represented by box-and-
whisker plots and median parameter values and interquartile ranges; bars 
extending to 1.5x the interquartile range are shown for each drug as a measure 
of variance. Parameter values for outlier cell lines are marked with asterisks. 
Compounds are sorted on the basis of the median IC50 value. Drug targets are 
nominal and do not include off-target effects (Fallahi-Sichani et al., 2013). 
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1.3.5.3 Principal component analysis (PCA) 
Principal component analysis (PCA) is a dimensionality reduction method 
that rotates the high-dimensional data set, seeking to capture most variance in a 
small number of successively chosen orthogonal axes of measurement 
combinations. PCA can be thought of as fitting a quadratic surface with n 
dimensions to the data, where each axis of the surface represents a principal 
component. To find these axes, the averaged data points must be subtracted 
from the origin in order to zero-center the data points. Then, a covariance matrix 
of the data points needs to be computed so that the eigenvalues with their 
corresponding eigenvectors could be calculated.  
The principal components are defined by weighting signals with high 
covariance and de-emphasizing signals that show little covariation with other 
signals. In this way, PCA condenses measurements to highlight the global 
patterns in the data set as reflected by just two or three dimensions that capture 
the maximal covariation between all of the signals (Janes and Yaffe, 2006; 
Wikipedia, 2015). 
1.3.5.4 K-means clustering 
Clustering is a simple data-mining tool for analyzing large-scale datasets. 
Many clustering methods are based on global optimization of a criterion that 
measures compatibility of the clustering result to the data. K-means and mixture 
Gaussian model-based clustering are examples of this category (Tseng, 2007). 
K-means clustering is an unsupervised learning algorithm that solves the well-
known clustering problem. This statistical clustering method that partitions n data 
points into k clusters in a way that each observation will belong to the cluster with 
the closest mean. To start the clustering, k center-points need to be defined for 
each cluster. These center-points are placed as far as possible in respect to each 
other. Then, data points from each cluster are assigned to nearest center-points 
until there are no data points left. Afterwards, new center-points are calculated 
which might lead to a change in their location and the process is repeated until 
the cluster centroids do not reposition anymore. Therefore, the drawback of this 
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method is that it heavily dependens on the prior selection of the center-points 
(Abdul Nazeer and Sebastian, 2010). 
1.3.5.5 viSNE (Stochastic Neighboring Embedding) 
Reducing the dimensionality of data involving heterogeneous cell 
populations can be accomplished using t-distributed stochastic neighbor 
embedding (t-SNE) (Maaten and Hinton, 2008) which projects cell populations in 
a two-dimensional space while attempting to preserve local neighbor 
relationships. SNE methods accomplish this by distributing data points so that 
distributions of pairwise similarity scores for each point to all others are minimally 
divergent between the original and the projected data (Hinton and Roweis, 2002). 
To obtain a flat projection that better retains the heterogeneity of cells than the 
projection of k-means clusters, t-SNE implementation viSNE could be used as an 
alternative approach motivated for the analysis of CyTOF data (Amir el et al., 
2013). 
1.3.5.6 Wanderlust 
Because cells in normally growing populations of cells are present at 
different points in the cell cycle, it is possible to reconstruct cell cycle trajectories 
from certain kinds of fixed cell data (Kafri et al., 2013). A widely used method to 
this end is the Wanderlust algorithm (Bendall et al., 2014), which connects paths 
of nearest neighbors among subsampled single-cell readouts in order to place 
cells on a shared axis that may correspond to progression through a 
differentiation program or the cell cycle (Gut et al., 2015). 
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3. RESULTS 
1.4 Dissecting population averaged drug response 
1.4.1 Results from high-content immunofluorescence (IF) 
imaging and biochemical methods 
1.4.1.1 Multiparametric analysis of dose-response curves 
We derived different dose-response parameters from each individual 
curve, including GI50, AUC, Hill slope (HS), and Emax. Instead of reporting a single 
parameter as a measure of potency or efficacy, we plotted pairwise combinations 
against each other while surmising dependencies between some parameters and 
target identity. Overall, MEK inhibitors (PD0325901 and Selumetinib) were most 
potent in inhibiting growth, followed by mTOR (Dactolisib and PP242) and EGFR 
(Gefitinib and Erlotinib) inhibitors, and AKT targeting drugs (MK2206 and 
Triciribine) were least potent (Figure 3.1). This ranking of target classes by 
potency was largely consistent between AUC and GI50.  
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Figure 3.1 Measurement of drug potency by pairwise combinations of two 
parameters. 
Rank orders of most potent to least potent inhibitors of growth in MCF10a cell 
line. MEK inhibitors (PD0325901 and Selumetinib in blue), mTOR inhibitors 
(Dactolisib and PP242 in black), EGFR inhibitors (Gefitinib, Erlotinib and 
Lapatinib in green) and AKT inhibitors (Triciribine and MK2206 in red). 
 
When maximal effect (Emax) was plotted against HS, drugs sharing a 
nominal target always cluster together. Among those clusters, EGFR targeting 
drugs implicate a much steeper HS than all other target classes. Furthermore, all 
drugs other than the AKT-targeting ones have very similar maximal cytostatic 
effects (Emax) (Figure 3.2). 
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Figure 3.2 Measurement of drug efficacy and hill slope reveals clusters 
based on drug target. 
All tested drugs with different targets (EGFR, MEK and mTOR) are effective in 
inhibiting growth at highest tested dose with Emax ~0.1, beside AKT inhibitors with 
Emax ~0.35. EGFR targeting drugs (Erlotinib, Gefitinib and Lapatinib) have much 
steeper hill slope (HS>1.5) compared to MEK-, AKT- and mTOR targeting drugs. 
 
1.4.1.2 Averaged signal-response parameters 
To explore differences in the signaling response between drugs, we 
averaged signals such as p-ERK1/2, p-S6, and p-4EBP1, which had shifting but 
always unimodal distributions across cells. We confirmed that MEK and EGFR 
drugs inhibited ERK signaling, but unexpectedly, AKT/mTOR drugs, in particular 
Torkinib, increased the phosphorylation of ERK1/2 in a dose-dependent manner. 
This suggests a feedback mechanism whereby mTOR activity negatively 
regulates ERK activation. Besides AKT inhibitors, which had no effect, and MEK 
inhibitors, which were minimally effective, other drugs fully suppressed S6 
phosphorylation, and only mTOR-targeting drugs fully suppressed 4E-BP 
phosphorylation (Figure 3.3).  
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Figure 3.3 Averaged signal analysis reveals significant molecular 
complexity underlying phenotypic differences. 
Dactolisib was very potent against p-S6 and p-4E-PB1, two proteins involved in 
translational control, whereas Selumetinib, which is even more potent as an 
inhibitor of cell growth, had little effect. In the case of the mTOR inhibitor 
(Torkinib), dose-dependent increase in p-ERK1/2 is evident. 
 
1.4.1.3 Dynamics of MAP kinase signaling in response to EGFR inhibitors 
In order to probe how dynamics of MAPK signaling relates to response to 
EGFR/ERBB2 inhibition, we treated a panel of 11 cell lines (four human 
mammary epithelial cells, four HER2 positive breast cancer cells and three lung 
cancer cell lines) with increasing dose of Lapatinib (9 doses and DMSO) and 
measured the phosphorylated levels of ERK1/2 after 1 hour and 6 hours and 
plotted the IC50 of p-ERK1/2 signal response curves at 1 hour in blue, 6 hour in 
green and the IC50 of the growth inhibition curve after 72 hours in red (Figure 
3.4). 
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Figure 3.4 MAPK dynamics in response to EGFR/HER2 inhibiting by 
lapatinib. 
Averaged p-ERK1/2 IC50 curves after 1 hour (blue) and 6 hours (green) and 
averaged GI50 curves after 72 hours (red) in 3 immortalized human mammary 
epithelial cells (MCF10a, HMLER, HMLE and hMEC), 4 HER2 positive breast 
cancer cells (21MT1, 21PT, SkBr3 and BT474) and 3 non-small cell lung cancer 
cell lines (H1666, H1650 and H3255). SkBr3, BT474, H1650 and H3255 are 
sensitive and the rest of the cell lines are resistant to lapatinib measured by the 
GI50. 
 
As it can be seen in Figure 3.4, in sensitive cell lines, where the GI50 
concentration is about 100 nM, the p-ERK1/2 IC50 does not change much over 
time. However in resistant cell lines, the IC50 of p-ERK1/2 signal response curve 
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is about 100 nM at 1 hour but it recovers after 6 hours of drug treatment. 
Moreover, the IC50 of p-ERK1/2 at 6 hours has a value similar to the IC50 of the 
growth inhibition curve at 72 hours. 
To examine the degree of correlation between early (1 hour) and 
intermediate (6 hours) p-ERK1/2 response and the late phenotypic response 
GI50, we calculated the linear correlation between these data points for all the cell 
lines. As it can be seen in Figure 3.5, there is a good linear relationship (R2=0.80) 
between the early signal and late phenotype and this correlation improves 
(R2=0.96) with time. 
 
 
 
Figure 3.5 Linear correlation between dynamics of p-ERK1/2 and growth 
inhibition. 
The x-axis shows the phenotypic response curves measured by GI50 and y-axis 
the IC50 of p-ERK1/2 signal response curves for all the cell lines. The left panel 
shows the correlation of the phenotype with p-ERK1/2 at 1 hour and the right 
panel shows the correlation between p-ERK1/2 and phenotype after 6 hours of 
drug exposure. 
 
This result shows the importance of MAPK signaling and its dynamics in 
response to EGFR/HER2 targeted inhibition. Among many possible mechanisms 
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that could explain the transient inactivation of MAPK signaling in response to 
EGFR/HER2 therapies, drug metabolization (Duckett and Cameron, 2010), efflux 
by ABC transporters (Sharom, 2008) and activation of autocrine loops (Gazdar 
and Minna, 2008) have been described extensively in the literature. To 
investigate whether the drug is still active post treatment, we treated MCF10a 
cells with increasing dose of Lapatinib for 5 hours and took the conditioned 
media and drug that have been on cells during this time and put it on fresh cells 
that had no memory of drug treatment and measured p-ERK1/2 activity after 1 
hour. Interestingly, the 1 hour signal response curve of the drug that had been on 
cells in total for 6 hours was very similar to the signal response curve of the drug 
that was only on cells for 1 hour. In addition, we performed a reverse experiment 
where we took the cells that have been in the presence of drug for 5 hours and 
put fresh media and drug on them for 1 hour. The resulting signal response curve 
was very similar to cells that have been in the presence of the drug for 6 hours 
(Figure 3.6). 
This result not only shows that the drug is not degraded and remains fully 
active after 6 hours but also indicates that the recovery is an induced state of 
cells, as cells that had the memory of being in the presence of drug remained 
resistant to p-ERK1/2 inhibition when exposed to fresh drug. 
Another possible mechanism for the recovery is activation of an autocrine 
loop or drug efflux that may potentially lead to reactivation of the drug target, the 
former by more extracellular EGF and thereby receptor activation and the latter 
by reducing the intracellular drug concentrations. To investigate this, we 
pretreated cells with Batimastat an inhibitor of ligand shedding and then treated 
cells with Cetuximab and EGFR neutralization antibody that competes with 
EGFR specific ligands. Surprisingly, the same behavior of p-ERK1/2 signaling 
was observed with Cetuximab in the absence or presence of Batimastat, 
providing evidence that EGFR autocrine loop is not the cause of recovery (Figure 
3.7). 
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Figure 3.6 p-ERK1/2 recovery is an induced state. 
Averaged p-ERK1/2 signal responses to Lapatinib were assessed in 4 different 
conditions. p-ERK1/2 signal response after 1 hour (blue) treatment with fresh 
Lapatinib, after 6 hours (green) of treatment with fresh Lapatinib, after 1 hour of 
treatment with Lapatinib that was exposed to cells for 5 hours (yellow) and after 1 
hours of treatment with fresh Lapatinib on cells pretreated with the drug for 5 
hours (red). 
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Figure 3.7 p-ERK1/2 recovery is not regulated by an autocrine loop 
activation. 
Averaged p-ERK1/2 signal response to Cetuximab (Erbitux) in the presence or 
absence of Batimastat a ligand shedding inhibitor. p-ERK1/2 signal response 
curve after 1 hour of exposure to Erbitux in the presence of Batimastat (blue), 
after 1 hour of exposure to Erbitux in the absence of Batimastat (green), after 6 
hour of exposure to Erbitux in presence of Batimastat (yellow) and after 6 hour of 
exposure to Erbitux in the absence of Batimastat (red). 
 
Furthermore, Cetuximab cannot be a substrate for an ABC transporter and 
the evidence in the literature (Dai et al., 2008) shows that Lapatinib is rather an 
inhibitor of ABCG2 drug pumps. However, observing similar results from small-
molecule and antibody inhibition pointed us to the drug target itself.  
1.4.1.4 Dynamics of drug target inhibition 
To quantify the activity of EGFR/HER2, we performed quantitative ELISA 
on a subset of cell lines treated with 1 μM Lapatinib. Figure 3.8 shows that after 1 
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hour with Lapatinib, p-EGFR and p-HER2 are fully inhibited in all cell lines. 
However, after 6 hours, both drug targets get reactivated in resistant cell lines, 
while they remain inactive in sensitive cell lines. 
 
 
Figure 3.8 Recovery of MAP kinase signaling is regulated at the receptor 
level. 
Phosphorylated levels of EGFR and HER2; Lapatinib targets were quantified by 
ELISA. Both phosphorylated forms of EGFR and HER2 are inhibited after 1 hour 
of exposure to Lapatinib, however both targets recover only in resistant cell lines. 
Top panel shows phosphorylated EGFR at Tyr1068 residue and the bottom 
panel shows phosphorylated levels of HER2 at Tyr1221/1222 residues. 
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To investigate the origin of this recovery we used high-content imaging 
and western blot analysis to have a relative view on the localization and activity 
of the receptor (EGFR). 
 
 
 
Figure 3.9 Total EGFR localizations in response to lapatinib in full serum. 
EGFR localization in full serum media after 1 or 6 hours treatment with DMSO or 
1 µM lapatinib. 
 
As it can be seen in Figure 3.9, EGFR in cells cultured in full serum media 
seem to be internalized, detected as punctuates inside the cell. However, 1 hour 
post Lapatinib treatment, the EGFR punctuates quantified as spots seem to 
diffuse rapidly accompanied by reduction of clathrin heavy chain spots with a 
very similar rate (Figure 3.10). The rate seems to decline between 1 hour and 6 
hours in a way that the ratio of total levels and membrane levels of EGFR remain 
constant but both increase during these time points. The phosphorylation of the 
receptor at two different sites and its direct downstream binding protein Shc 
seems to follow the same trend which is inhibition at 1 hour accompanied by 
subsequent recovery and reactivation later on. 
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Figure 3.10 Recovery of EGFR phosphorylation is accompanied by EGFR 
translocation to plasma membrane. 
Phosphorylated levels of EGFR at Tyr1068 and Tyr1173 residues get inhibited 
after 1 hour of drug exposure. This reduction is associated with a sharp decline in 
the number of EGFR and clathrin heavy chain punctuates as well as increased 
levels of EGFR localization at the cell membrane. The number of EGFR and 
clathrin heavy chain spots flat out after 1 hour, while the membrane levels of 
EGFR continue to rise during the process of p-EGFR recovery. 
 
1.4.1.5 Drug combination to overcome recovery 
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We argue that localization of the receptor at cell membrane facilitates 
ligand binding and thereby causes activation of the reserved receptor that was 
internalized prior to drug treatment. 
Due to post-treatment recovery of the drug target itself, we examined 
combined treatment of Lapatinib with Erlotinib, another EGFR inhibitor. In other 
words, we hypothesized that inhibiting the activity of the same target with multiple 
drugs would likely lead to sustained inhibition (Figure 3.11). 
 
 
Figure 3.11 Sustained inhibition of p-ERK1/2 by drug combination. 
On the x-axis increasing doses of Lapatinib was combined with increasing doses 
of Erlotinib on the y-axis of a 96-well plate and p-ERK1/2 was measured. Single-
cell frequency plots for cells in each well show how the population behaves 
across dose combinations. Red color indicates high levels and black indicates 
low levels of p-ERK1/2. 
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Figure 3.12 Combination of EGFR targeting drugs leads to sustained 
inhibition of proliferation signaling. 
On the x-axis increasing doses of lapatinib was combined with increasing doses 
of Erlotinib on the y-axis of a 96-well plate and p-Rb was measured. Single-cell 
frequency plots for cells in each well show how the population behaves across 
dose combinations. Red color indicates high levels and black indicates low levels 
of p-Rb. 
 
As it can be seen in Figures 3.11 and 3.12 at the level of p-ERK1/2 and p-
RB, Lapatinib combined with Erlotinib leads to a synergistic effect resulting in a 
full and sustained inhibition of these signals compared to Lapatinib alone after 24 
hours of drug treatment. 
 
1.4.1.6 Principal component analysis of drug response data 
To explore the space of signaling changes in response to all drugs along 
all measured signaling markers, we performed principal component analysis 
(PCA) over all drug treated conditions after normalizing bulk signals against 
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DMSO-treated samples and converting into log ratios. PCA rotates the high-
dimensional data set, seeking to capture most variance in a small number of 
successively chosen orthogonal axes of stain combinations. We found that two 
such principal component axes alone were sufficient to capture 88% of all 
variance, indicating that the bulk signaling changes in response to each of the 
tested drugs collectively occurred in a flat plane (Figure 3.13). Increasing doses 
of kinase inhibitors perturbed the bulk signaling state of cells in a characteristic 
direction for each target class. While all MEK, EGFR, and mTOR inhibitors 
reduced signals along the first component, which was largely a projection of p-
CDK2, differences in the effects between target classes lied mostly in ERK 
activation and p-S6. p-ERK1/2 was the largest negative loading of the second 
principal component, and suppression of p-S6 and p-4E-BP were strongly 
positive loadings of both. This largely reflects induction of p-ERK1/2 by mTOR 
inhibitors and a declining effect of drugs on p-S6 and p-4E-BP from mTOR 
inhibitors, which were strong suppressors, over EGFR inhibitors to MEK 
inhibitors, which had no effect. The signaling axis along the cell growth markers 
p-S6 and p-4E-BP was virtually orthogonal to that of the cell cycle progression 
markers p-CDK2 (see compass inset) and p-Rb.  
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Figure 3.13 Principal component analysis (PCA) of drug effects clusters 
inhibitors that have similar nominal targets. 
PCA analysis of MEK inhibitors (PD0325901 and Selumetinib), EGFR inhibitors 
(Erlotinib, Gefitinib and Lapatinib) AKT inhibitors (Triciribine and MK2206) and 
mTOR inhibitors (Dactolisib and Torkinib). 
 
To challenge this interpretation with an alternative analysis, we normalized 
the log ratios by the standard deviation of each signal in freely cycling cells. 
Intuitively, this normalization emphasizes drug-induced changes in signaling 
markers that are otherwise more tightly regulated. The corresponding PCA 
therefore yielded different loadings, with the direct CDK2 inhibitory protein p27 as 
the main loading of the first principal component, and p-AKT and p-4E-BP as the 
main loadings of the second (Figure 3.13). The projection of drug effects along 
the p27/Kip1 axis was oriented in opposite direction to the p-CDK2 axis in Figure 
3.12, consistent with mutually antagonistic interactions between CDK2 and 
p27/Kip1. While the protein synthesis marker p-4E-BP was shared between the 
second principal components of both analyses, the mTOR regulator AKT and the 
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mTOR substrate p-S6 were concordant readouts of growth regulation as well. 
This confirms that the bulk signaling changes in response to treatment with drugs 
from the kinase inhibitor panel largely occur within a plane spanned by growth 
and cell cycle progression axes. 
 
 
Figure 3.14 Principal component analysis (PCA) of drug effects clusters 
inhibitors that have similar nominal targets. 
PCA analysis of MEK inhibitors (PD0325901 and Selumetinib), EGFR inhibitors 
(Erlotinib, Gefitinib and Lapatinib) AKT inhibitors (Triciribine and MK2206) and 
mTOR inhibitors (Dactolisib and Torkinib). PC1 and PC2 in this PCA model are 
indicated with an apostrophe in the text. 
 
p27/
Kip1
p57/
Kip2
p4EBP1
EGFR
mTOR
MEK
AKT
-0.01        0        0.01     0.02      0.03      0.04     0.05
0.015 
0.01 
0.005 
-0.005 
0 
-0.01 
-0.015 
-0.02 
-0.025 
-0.03 
-0.035 
PC1
PC
2
Selumetinib
PD0325901
Erlotinib
Gefitinib
Lapatinib
MK2206
Triciribine
Dactolisib
Torkinib
 56 
1.5 Dissecting single-cell level variability in drug response 
1.5.1 Results from high-content immunofluorescence (IF) 
imaging 
1.5.1.1 Fractional analysis of signal-response curves 
To test the predictive value of some of the strongest loadings of the PCA 
model, we first integrated those signals over all doses by computing the AUCs of 
the p-ERK1/2, p-S6, and p-CDK2 mean signals. Because some of these signals 
where highly variable from cell to cell (Figure 3.15), we also calculated the AUCs 
of the fractions of cells that either p-CDK2 positive or were p-CDK2/p-Rb double 
positive after treatment with drugs for 24 hours. 
 
 
Figure 3.15 Representative images of graded and on or off signals. 
Representative images of population of cells stained with Hoechst dye and 
Whole Cell Blue to label nuclei and cytoplasm (blue) as well as stained with 
primary mouse p27/Kip1 antibody (green), goat p-Rb antibody (orange) and 
rabbit p-CDK2 antibody (red) together with respective species-specific secondary 
antibodies. p27/Kip1 has a graded distribution across single cells compared to p-
Rb that is either on or off and p-CDK2 signal that is either on or off and either 
cytoplasmic or nuclear. Bars correspond to ~10 µm. 
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We then assessed the correlation of these metrics with the AUC of growth 
inhibition after 48 hours (Figure 3.16). We found no significant correlation 
between the phenotypic response (AUC of GI50 after 48 hours) and the AUC of 
upstream signaling nodes such as p-ERK or p-S6. However, p-CDK2, a 
downstream cell cycle regulator showed a much better linear relationship with the 
48-hour phenotype. This correlation significantly improved when the fraction of p-
CDK2 positive cells was used instead of the mean p-CDK2 signal. Notably, the 
fraction of p-CDK2/p-Rb double positive cells did not improve predictions beyond 
using p-CDK2 alone, thus emphasizing the crucial role of CDK2 in controlling 
drug response upstream of p-Rb in MCF10A cells. More generally, the results 
show that an analysis based on fractions of positive or negative cells can be 
more informative of drug response signaling than simply using population 
averages.  
 
Figure 3.16 Single-cell fractions better predict growth inhibition phenotype. 
The linear correlation between AUC of signal response curves of phospho-
specific measured markers (strongest loadings of PCA model) (p-ERK1/2, p-S6, 
p-CDK2 as well as positive p-CDK2 fraction and p-CDK2 and p-Rb double 
positive fraction) after 24 hours and the AUC of growth inhibition curve after 48 
hours. Statstical significance was assessed by Fisher’s r-to-z transformation. 
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1.5.1.2 Single-cell visualization of cytostatic states 
To assess the role of the strongest loadings in the second PCA model 
(Figure 3.14), we plotted the single-cell drug responses of Cyclin-dependent 
kinase inhibitors (CDKIs) p21/Cip1, p27/Kip1, and p57/Kip2 against p-RB for the 
maximal tested drug dose (10 µM, Figure 3.17). We found that EGFR- and MEK-
targeting drugs caused an accumulation of these CDKIs, whereas mTOR drugs 
not only failed to increase p27/Kip1 and p57/Kip2 levels, they even led to a 
reduction in p21/Cip1. This was similar for AKT inhibitors, which we showed not 
to be effective in inhibiting growth. These results illustrate the value of high-
content imaging compared to methods that measure viability or surrogates such 
as ATP concentrations, while EGFR-, MEK- and mTOR-targeting drugs shared 
similar Emax, yet our high-content molecular analysis revealed quite different 
cytostatic states. 
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Figure 3.17 Molecular details of cytostasis are different from one drug to 
the next. 
Abundance of CDKIs (p21/Cip1, p27/Kip1 and p57/Kip2) was assessed across 
non-treated cells and highest tested dose of 3 inhibitors of EGFR (Lapatinib), 
MEK (Selumetinib) and mTOR (Torkinib). Unlike mTOR inhibitor (Torkinib) that 
shows reduction in p21/Cip1 and no induction of p27/Kip1 and p57/Kip2, EGFR- 
(Lapatinib) and MEK- (Selumetinib) targeting drugs lead to upregulation of all 
measured CDKIs. 
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1.5.2 Results from cyclic immunofluorescence (CycIF) imaging 
1.5.2.1 K-means clustering in PCA space 
Cell cycle regulators have previously been implicated as drivers of 
phenotypic cell-to-cell variability (Buettner et al., 2015; Overton et al., 2014; Patel 
et al., 2014; Powers and Satija, 2015) (Figure 3.15). Because different drugs also 
elicited distinct co-distributions of p-Rb with the CDKI proteins p21/Cip1, 
p27/Kip1, and p57/Kip2 in pairwise co-stained MCF10A cultures, we decided to 
escalate the dimensionality of observed co-distributions to 19 signaling readouts 
by means of CycIF measurements after 24 hours of drug treatment. To survey 
unperturbed cultures for distinct subpopulations, we conducted k-means 
clustering, starting with k = 5 and using the cosine distance metric, which 
distinguishes the directions of marker combinations in signaling space. We then 
iteratively merged clusters while projections along pairwise centroid lines were 
not bimodal. Because this procedure yielded k = 3 well-defined clusters, we 
projected the single-cell densities into the plane defined by cluster centroids 
(Figure 3.18). This projection revealed a difference between the two most 
populated clusters mostly in an increase in p-Rb, PCNA, and a decrease in the 
quiescence marker p27/Kip1. These clusters thus corresponded to proliferating 
(blue) and non-proliferating cells (black). A third, much less populated cluster 
(red) could be distinguished from the remaining population by a large increase in 
γ-H2A.X, p-Histone H3, and pan-p-Aurora staining, each indicative of the mitotic 
fraction. This shows that our dataset captures at least three distinct proliferation 
states in unperturbed cultures. 
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Figure 3.18 k-means clustering in unperturbed cells reveals existence 3 
distinct cellular states corresponding to cell cycle. 
K-means clustering of CycIF data from unperturbed cells showed 3 cluster 
centers corresponding to quiescence enriched with low levels of p-Rb, p-S6, 
PCNA (black) and proliferation enriched with high levels of p-Rb, p-S6, PCNA 
(blue) and mitotic state enriched with p-Aurora and p-Histone H3 (red). 
 
To explore and compare the effects of kinase inhibitors on single-cell co-
distributions, we first performed a PCA on all drug-induced shifts of population 
averages as we did for the dataset obtained by conventional IF microscopy. In 
agreement with the conventional dataset, the plane spanned by the first two 
principal components (Figure 3.19) described drug-induced changes that were 
separable between p-S6 and p-Rb (compass inset). The second principal 
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component reproduced the induction of p27/Kip1 in response to MEK inhibition 
by Selumetinib that we had observed in traditional IF experiments, and made for 
an additional reduction in p-Rb. Overall, our coarse analysis raises the 
hypothesis that p27/Kip1 induction due to MEK inhibition is a critical mechanism 
that distinguishes kinase inhibitors in their ability to suppress p-Rb-mediated cell 
cycle progression. 
 
 
Figure 3.19 Principal component analysis (PCA) of CycIF data is consistent 
with conventional IF data. 
PCA analysis of 3 drugs targeting MEK (Selumetinib), EGFR (Lapatinib) and 
mTOR (Torkinib). Increasing drug doses are illustrated by increasing sizes of 
symbols for each drug. 
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We then used the PCA-derived transformation to project single-cell states 
into density plots for increasing concentrations of kinase inhibitors (Figure 3.20). 
The projection revealed a bimodal distribution of proliferation markers in cells 
treated with DMSO alone, with the largest fraction corresponding to cells 
expressing high abundances of p27/Kip1. Treatment with high concentrations of 
any one drug yielded tight unimodal distributions, but Lapatinib- and Selumetinib-
treated cells congregated in a state with higher p27/Kip1 concentrations than 
Torkinib-treated cells. The density plot for cells treated with a close to IC50 
concentration of Selumetinib revealed that the highest bulk abundance of 
p27/Kip1 comprised of unusually disperse single-cell distributions. A limitation of 
this analysis is, however, that the linear projection based on bulk changes is 
unlikely to capture the full heterogeneity of cells. 
 
 
Figure 3.20 Single-cell projection on k-means clusters in PCA space 
reveals differential cytostatic states. 
Single-cell projection of k-mean cluster in presence of increasing doses of 3 
drugs targeting MEK (Selumetinib), EGFR (Lapatinib) and mTOR (Torkinib) 
shows differential single-cell distributions. 
 
1.5.2.2 viSNE visualization of drug response data 
It is in fact challenging to visualize high-dimensional single-cells data in bi-
axial plots and typically dimension reduction methods fail to give good 
separations of single cells in higher dimension.  Thus, we applied a non-linear 
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stochastic neighboring embedding dimension-reduction method (viSNE), which 
retains high-dimensional structure of data but yields better separations in 
different sub-populations with distinct signatures. First, four replicates of 
control/DMSO-treated samples were analyzed by viSNE, and as expected all 
controls are inseparable (Figure 3.21). 
 
Figure 3.21 DMSO-treated cells in viSNE space are inseparable. 
4 independent DMSO-treated samples were compared using viSNE analysis 
showing that they occupy the same domains in viSNE projection. 
 
However, examining drug-treated samples, shows distinct sub-domains on 
the viSNE projects, with clear DMSO occupied domain, mTOR/PI3K drugs 
(Torkinib and Dactolisib) domain and overlapping but still distinguishable domain 
consisted by EGFR/MEK drugs (Lapatinib and Selumetinib) (Figure 3.22). 
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Figure 3.22 viSNE analysis of perturbed cells implies drug specific induced 
subpopulations. 
Single-cell viSNE analysis of drug perturbed states at the GI50 concentrations. 
DMSO-treated sample (blue), MEK inhibitor (Selumetinib, pink), EGFR inhibitor 
(Lapatinib, green), PI3K-mTOR inhibitor (Dactolisib, red) and mTOR inhibitor 
(Torkinib, black) populate different subdomains. 
 
For the purpose of mapping single-cell heterogeneity in drug induced 
states, we separated the data by drug target, which further separated clear 
differences compared to DMSO-treated cells for each drug at the GI50 
concentration (Figure 3.23). 
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Figure 3.23 viSNE analysis of single drugs implies similarity in single-cell 
phenotypes across drug target subsets. 
Single-cell viSNE analysis of drug perturbed states at the GI50 concentrations. 
DMSO-treated sample (blue), MEK inhibitor (Selumetinib, pink), EGFR inhibitor 
(Lapatinib, green), PI3K-mTOR inhibitor (Dactolisib, red) and mTOR inhibitor 
(Torkinib, black) populate different subdomains. MEK and EGFR inhibitors are 
similar but distinguishable and PI3K-mTOR inhibitor and mTOR inhibitors show 
high degree of similarity. 
 
These results indicate the power of single-cell visualization of CycIF data 
using viSNE algorithm for potential application in preclinical drug discovery. In 
order to investigate the variation in single-cell drug responses at the level of 
signaling, we further examined the distribution of each individual signal by viSNE. 
As shown in Figure 3.24, viSNE plots indicated that Ki-67 covers the most area 
of cycling cells, while PCNA and p-RB labeled different subsets of proliferative 
cells. Interestingly, while Cyclin D1 is normally considered as a proliferative 
marker, high Cyclin D1 cells were p-RB negative and with strong p21/Cip1 and 
p53 staining. As previous studies suggested, the subpopulation might correspond 
to quiescent or senescent states that may be induced by drugs (Chen et al., 
2013). By comparing the distribution of signals and their corresponding drug 
treatments, we found that similar to conventional (IF) results, EGFR and MEK 
inhibitor (Lapatinib and Selumetinib) treated cells have relatively high levels of 
p27/Kip1 and FOXO3a compared to mTOR inhibitors (Dactolisib and Torkinib). In 
addition, we examined the distributions of p-ERK1/2 and p-S6, signals upstream 
of cell cycle regulators as well as downstream targets of the inhibitors. As we 
expected, two p-S6 sites are decreased by mTOR targeting drugs and the cells 
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with highest p-ERK signal seem to be enriched in the mTOR inhibitor treated 
cells, which agreed with the previous findings on the negative feedback loop 
between PI3K/mTOR and ERK pathways (Carracedo et al., 2008). Lastly, 
although the Ki-67 plot indicates all these drugs efficiently put cells into non-
proliferative state, the γH2A.X plot suggests that the overall DNA damage/cell 
death were low in these treatments. 
 
 
Figure 3.24 viSNE analysis of drug induced domains across 12 signals 
reveals distinct signaling states across different drugs. 
Assessment of enrichment of 12 different drug induced signals in viSNE space. 
Proliferation markers (Ki-67, PCNA, p-Rb and Cyclin D1) occupy differential 
domains in viSNE space. Cyclin-dependent kinase inhibitor p21/Cip1 occupies 
similar domains as p53, while p27/Kip1 occupies similar domain as Foxo3a. p-
ERK1/2 remains active in some cells and different active phospho residues on 
S6 occupy similar single-cell domains. 
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1.5.2.3 Fractional analysis in viSNE space 
In addition to probing the overall signaling responses of different drugs by 
viSNE, we took advantage of multi-dimensional single-cell data to dissect 
different phenotypic responses of subpopulations. We resampled the Torkinib 
treated cells into 3 different sub-populations by gating their p-Rb levels. 
Surprisingly, we found that cells high with p-RB (drug resistant cells) are mostly 
enriched in S/G2, with high Ki-67, PCNA and low p21/Cip1 (Figure 3.25). We also 
found that these resistant cells might have slightly higher total-AKT, which may 
account for sensitivity to PI3K/mTOR inhibition.  
 
 
Figure 3.25 Torkinib resistant subpopulation is in S/G2 cell cycle phase and 
enriched with markers of proliferation. 
In viSNE space, cells that were treated with Torkinib were gated based of p-Rb 
levels (high, medium and low) (left panel). Cells that are high with p-Rb signal in 
presence of drug seem to be in S/G2 cell cycle phase based on DNA content and 
enriched with markers of proliferation (Pan-AKT, PCNA and Ki-67, left panel). 
Cells with low p-Rb signal seem to have high levels of p21/Cip1. 
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1.5.2.4 Wanderlust visualization of steady states 
Even though, the viSNE algorithm was powerful in visualizing high-
dimensional subpopulation differences in mTOR targeting drugs by keeping 
single-cell information intact, due to static representation of the signals in such 
analysis, it lackes clear information on transitional states. Thus, we addressed 
this issue by performing Wanderlust algorithm on CycIF dataset initially for cell 
cycle regulating proteins in unperturbed cells (Figure 3.26).  
 
Figure 3.26 Single-cell distribution of cell cycle markers in viSNE space 
combined with Wanderlust axis recapitulates direction of cell cycle 
progression. 
Single-cell distributions of cell cycle markers such as p-Rb, Ki-67 and p21/Cip1 in 
single cells shows distinct cellular states. Wanderlust overlay on viSNE space 
shows the direction of cell cycle progression (bottom right). 
 
Additionally, we were able to reconstitute different stages of cell cycle from 
Wanderlust trajectory. In G0/G1 stage, DNA content is the lowest accompanied by 
−40 −20 0 20 40
−20
0
20
 
bh−SNE1
p-RB
 
bh
−S
N
E2
4
5
6
7
−40 −20 0 20 40
−20
0
20
 
bh−SNE1
p21
 
bh
−S
N
E2
4
5
6
7
−40 −20 0 20 40
−20
0
20
 
bh−SNE1
Ki-67
 
bh
−S
N
E2
2
4
6
8
−40 −20 0 20 40
−20
0
20
 
bh−SNE1
wanderlust
 
bh
−S
N
E2
98
102
106
 70 
low levels of p-RB and rising levels of Ki-67, PCNA and Cyclin D1 as well as 
accumulation of p27/Kip1 and p21/Cip1. In G1/S phase, levels of Ki-67 and 
Cyclin D1 continue to rise at a slower rate, whereas PCNA levels do not rise 
much while the levels of p27/Kip1 and p21/Cip1 decline, former with a slow and 
latter with a faster rate until cells pass the restriction point and commit to DNA 
synthesis that is accompanied by a sharp increase of p-RB. In S/G2/M cell cycle 
stage, p27/Kip1 and p21/Cip1 continue to degrade with similar rates 
accompanied by degradation of Cyclin D1 and this time levels of Ki-67 reach a 
plateau, while the PCNA levels sharply rise (Figure 3.27).  
 
Figure 3.27 Reconstruction of cell cycle progression by Wanderlust 
analysis of static cell cycle regulator markers. 
Different markers of cell cycle progression such as p-Rb, p21/Cip1, p27/Kip1, 
Cyclin D1, PCNA, Ki-67 and DNA content were measured in unperturbed cells 
and Wanderlust analysis correctly reconstituted G0/G1, G1/S and G2/M cell cycle 
stages. 
 
In principal, Wanderlust graph-based trajectory reconstruction is useful in 
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continuous system such as cell cycle. However, it is able to reconstruct only non-
branching trajectories, underlining a requirement for different analytical methods 
to study bifurcating cell populations. This is crucial as we show in the viSNE 
section that all tested drugs generated significant cell-to-cell heterogeneity, 
particularly when their response was incomplete (Emax>0). Different 
subpopulations of cells arise in this case because of branching in cell cycle 
trajectories, with some cells exiting the cell cycle and others continuing to 
proliferate. Newly developed algorithms such as Wishbone (Setty et al., 2016) 
can deal with bifurcations in developmental systems, however to the best of our 
knowledge have not been tested in pharmacology so far. 
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4. DISCUSSION 
 
Discovery and development of new medicines is expensive and prone to 
failures (Bains, 2004; Swinney and Anthony, 2011). Reducing the high cost of 
failures could remove a huge burden from pharmaceutical companies and opens 
possibilities to focus investments on R&D in a more productive manner. Among 
many reasons for failure in development of new drugs, safety and efficacy seem 
to play a major role (Hughes et al., 2011). While there are only limited 
approaches to assess drug safety in preclinical studies, the potential applications 
of novel technologies and computational frameworks in preclinical stages of drug 
discovery is evident (Sorger et al., 2011). Recruitment of such approaches in 
early phases of drug development will likely lead to lower number of potential 
drug candidates progressing to late clinical phases, but at the same time 
increases the likelihood of success in a few rigorously tested safe, potent and 
effective chemical agents to be approved and used in therapy (Paul et al., 2010). 
Understanding the molecular mechanisms of drug action requires 
characterizing drug-induced changes in cellular states. In the case of targeted 
anti-cancer drugs these typically involve inhibition of oncogene signaling, 
changes in cell cycle distribution and induction of senescence or apoptosis. 
Conventional high-throughput screening approaches that examine bulk drug 
effects fail to systematically assess this complexity and multiplex methods are 
required to collect well-average drug dose-response data for multiple molecular 
signals and cellular phenotypes along a response pathway. Because imaging 
allows data to be acquired at relatively low cost, it is feasible to obtain detailed 
information on the impact of dose and time across multiple compounds. We 
believe that this will be particularly useful in the later stages of pre-clinical drug 
development in which the aim is to select candidates among dozens of lead 
compounds with similar structures (structure-activity relationships). 
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In this thesis, we have shown that microscopy represents effective means 
to characterize differences among drugs that relate to drug resistance or 
sensitivity. We show how the focus to date on drug potency (typically IC50 or 
AUC) ignores the potential impact and biological importance of variation in other 
parameters, such as the steepness of the dose-response curve hill slope (HS) or 
differences in maximum effect (Emax). Interestingly, analysis of drug dose-
response curves revealed that within effective drug groups, drugs that have 
different potency seem to lead to similar levels of growth inhibition at highest 
tested dose of each drug. In addition, unlike drugs that target intracellular 
biochemical nodes like MEK (PD0325901 and Selumetinib), AKT (MK2206 and 
Triciribine) or mTOR (Dactolisib and Torkinib) that have shallow dose response 
curves (HS<~1), EGF receptor targeting drugs (Erlotinib, Gefitinib and Lapatinib) 
lead to much steeper dose responses (HS >1.5). 
Averaged analysis of activity for a few signaling kinases like p-ERK1/2, p-
S6 and p-4EB-BP1 post perturbation with the drug panel, revealed significant 
molecular complexity underlying the phenotypic differences. For example, the 
PI3K/mTOR inhibitor Dactolisib was a very potent suppressor of the 
phosphorylation of S6 and 4E-BP1, two major proteins involved in translational 
control, whereas Selumetinib, which is even more potent as an inhibitor of cell 
growth, had little effect. In the case of the mTOR inhibitor Torkinib, we observed 
dose-dependent increases in p-ERK1/2, a pro-growth counter therapeutic effect 
consistent with negative regulation of MAP kinase signaling by mTOR. 
To investigate the role of MAPK signaling in drug response and 
importance of time and dose on phenotypic regulation, we screened the 
response of a panel of non-transformed as well as cancer cell lines to Lapatinib; 
an FDA approved small-molecule dual tyrosine kinase inhibitor targeting 
EGFR/HER2 and showed that the dynamics of ERK phosphorylation is important 
in predicting the response to Lapatinib in a way that ERK phosphorylation is a 
good predictor of late phenotypic response only at intermediate time points. In 
fact, unlike intermediate p-ERK1/2 response, early-immediate p-ERK1/2 signal 
response can only poorly predict the phenotype. We investigated the origins of p-
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ERK1/2 recovery post treatment with Lapatinib in one of the resistant cell lines 
(MCF10a) by providing evidence against drug efflux, metabolization or activation 
of an autocrine loop. 
Through time series experiments, using combination of high-content 
imaging, ELISA and western blot methods we provided evidence toward a 
dynamic behavior of drug target (EGFR/HER2) post exposure to Lapatinib. Since 
our aim was to examine a focused case in a typical protocol used in high-
throughput drug screens, we assessed Lapatinib response using the exact 
protocol. In this protocol drug is combined with full serum media and added to 
cells, which could influence cell signaling in steady state. In basal conditions, 
most EGFR seemed to be localized in the cytosol as punctuates, likely in 
multivesicular bodies. Upon drug exposure, immediate reduction in EGFR 
phosphorylation at multiple residues is detected, cytosolic EGFR translocates to 
plasma membrane, where it has access to extracellular EGF ligand in the full 
serum media, which in turn leads to EGFR reactivation and p-ERK1/2 recovery. 
This translocation was associated with a reduction in the number of intracellular 
EGFR and clathrin heavy chain punctates suggesting a clathrin-mediated 
receptor internalization in basal conditions. In order to sustain EGFR/ERK 
inhibition, we hypothesized that by combining two inhibitors for the same target 
(EGFR), we could not only sustain the EGFR/ERK inhibition by a synergistic 
effect, but also reduce the toxicity caused by high concentrations of drugs as 
each single agents used as monotherapy. In result, we observed that the 
combination of Lapatinib and Gefitinib caused p-ERK1/2 to remain inhibited as 
measured at 24 hours, which also resulted in the inhibition of a downstream cell 
cycle regulator (p-Rb). It is of importance to note that EGFR/ERK recovery only 
occurred at the Lapatinib concentrations below sub-saturation. In fact, the shift of 
p-ERK1/2 IC50 between immediate and intermediate time points happens only at 
concentrations below 3.2 nM suggesting that the activation of reserved 
intracellular EGFR fraction does not lead to recovery at high concentrations due 
to the presence of sufficient drug amounts of drug in the surrounding 
microenvironment. This alone, at least partially explains the steep hill slope of the 
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response to Lapatinib. Because all EGFR molecules need to remain inhibited in 
order to sustain pathway inhibition consistent with the regulation of EGFR activity 
by threshold effects (Sigismund et al., 2013). 
In order to identify the dominant signaling axis of drug response, we 
performed principal component analysis on bulk drug effects and applied PCA to 
the relative changes of signaling readouts. Two PCs captured ~90% of variance, 
indicating that the bulk signaling changes in response to all drugs explored in this 
dataset can be understood within a plane spanned by two axes. One axis (PC1) 
corresponded primarily to the phosphorylated levels of the CDK2 cell cycle 
kinase (p-CDK2). PC2 largely comprised p-ERK1/2 with negative loading and the 
phosphorylated forms of the ribosomal S6 subunit (p-S6S235/236) and of the 
translation repressor 4E-BP with positive loadings. S6 is activated by 
phosphorylation at multiple sites by TORC1 (Gonzalez et al., 2015) and by the 
p90 ribosomal S6 kinase (RSK; which in turn lies downstream of the MEK/ERK 
kinase cascade). Thus, virtually all of the effects of the nine drugs tested can be 
captured in a two-dimensional landscape in which proliferation (p-CDK2), MAPK 
signaling (p-ERK1/2) and protein translation (p-S6) are the most important 
molecular features.  
Dose-response trajectories were distinct for each target class, with PC2 
accounting for the greatest variation. For example, the AKT inhibitors (MK2206 
and Triciribine) resulted in dose-response trajectories that were similar to each 
other, yet distinct from those of the mTOR inhibitors (Dactolisib and Torkinib). 
The three ErbB receptor inhibitors tested, Gefitinib, Lapatinib and Erlotinib were 
also similar to each other, however distinct from all other drug classes. 
Altogether, the tight grouping of dose-response trajectories by drug class in 
signaling space suggests high selectivity of these compounds. The signaling 
plane identified by PCA also serves to illustrate that with increasing dose of 
mTOR drugs, the dose-response trajectories depart from a pure effect along the 
S6 axis and progressively induce mitogenic ERK signaling. In contrast, MEK 
inhibitors affected readouts more broadly and resulted in trajectories with many 
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other components orthogonal to the p-ERK1/2 vector. Thus, MEK inhibitors did 
not point in the opposite direction from p-ERK1/2. 
Multiple methods exist for normalizing and scaling experimental data prior 
to analysis methods such as PCA and it is not always clear which is the most 
appropriate method of choice for a given data set. Initially, raw intensity values 
obtained from image processing algorithms were divided by intensity values for 
DMSO only controls to obtain log2 fold-change ratios. As an alternative approach 
that aimed to highlight the elevated signaling states in drug-treated cells, log 
ratios were normalized by the cell-to-cell variability (as measured by standard 
deviation) for each IF signal in unperturbed cells. PCA of data normalized in this 
way yielded different loadings with the abundance of p27/Kip1 as the primary 
PC1’ loading and p-4E-BP1 as the primary PC2’ loading; PC1’ and PC2’ 
captured 75% of variance. Drug-response data projected differently in the PCA 
space defined by PC1’/PC2’ relative to PC1/PC2 but key biological features were 
retained. For example, in both cases drugs with similar targets mapped close 
together and drugs with different targets were distinct. PC1 and PC1’ were nearly 
the opposite of each other, consistent with mutually antagonistic interactions 
between CDK2 and p27/Kip1. With respect to PC2 and PC2’, it is reasonable to 
consider p-4E-BP1 as a stand-in for pS6, given that both lie downstream of 
AKT/mTOR. Thus, even though the two PCA plots appear to be different, they 
both capture the fact that the drugs tested move cells across a plane defined by 
cell cycle progression and protein translational activity. 
 
Single-cell profiling uncovers relationships between drug-target 
engagement and induction of cellular phenotypes that are obscured by 
population average methods, fitting well into the workflow of drug discovery. It 
can also be very economical with respect to reagents and numbers of cells (an 
important consideration with patient-derived materials). The data described in this 
thesis illustrate the potential of simple well-average data derived from imaging to 
characterize the diversity of cellular response to drugs. The analysis and insights 
are fundamentally similar to what can be achieved with multiplex biochemical 
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assays. However, for proteins and modification states that are bimodally 
distributed across the cell cycle, such as p-CDK2, averaging signals across an 
entire plate is suboptimal. We therefore compared the correlation between the 
computed AUC of average relative upstream signals such as p-ERK1/2 and p-S6 
as well as averages of most downstream signals such as p-CDK2 response 
curves and the AUC of the growth inhibition curve at 48 h and compared this to 
the correlation between fraction p-CDK2 positive fraction and phenotypic 
response. We observed no linear relationship between p-ERK1/2 or p-S6 and the 
phenotypes when all drugs were loaded in the model, however averaged p-CDK2 
response correlated well with growth inhibition (R2=0.71). A statistically 
significant (p=0.02 by Fisher’s r-to-z transformation test) improvement was 
achieved when instead of averaged p-CDK2, the fraction double-positive p-
CDK2/p-Rb fraction was used in the regression model (R2=0.91). 
Furthermore, to assess the molecular details of single-cell cytostatic 
phenotypes induced by drugs at the highest tested dose, we plotted of Cyclin-
dependent kinase inhibitors (CDKIs) (p21/Cip1, p27/Kip1 and p57/Kip2) 
abundance against p-Rb to quantify quiescent and proliferative subpopulation 
fractions. Analysis of the single-cell scatter plots revealed significant differences 
in molecular phenotypes induced by different drugs. Even though the averaged 
relative growth of all drugs, aside from AKT targeting-drugs were similar (Emax ~ 
1), mTOR targeting-drugs like Torkinib not only led to accumulation of p27/Kip1 
and p57/Kip2, but also reduced p21/Cip1 levels, whereas EGFR and MEK 
targeting-drugs perturbed all 3 CDKIs. These results underlie the value of high-
content single-cell microscopy in characterization of drug-induced cellular 
phenotypes, given that similar bulk growth inhibition does not necessarily 
correspond to similar cytostatic phenotype at single-cell level. 
Analysis of the well-average changes induced by a representative subset 
of the kinase inhibitors (one drug per target class) in the highly multiplexed CycIF 
dataset yielded comparable observations with respect to the underlying biology, 
although the sets of antibodies used for conventional IF and CycIF were largely 
distinct due to differing criteria for selection and optimization. For example, a 
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PCA of the well-averaged changes also revealed a planar surface that is 
sufficient to distinguish all drug classes. In this dataset as well, induction of 
p27/Kip1 is the major upstream distinction between the molecular effects of 
Torkinib, Lapatinib, and Selumetinib. A fundamental advantage of highly 
multiplexed single-cell measurements is the ability to reveal correlations between 
different signals within a population beyond the bulk changes. Such correlations 
can be used to infer functional relationships among proteins that are obscured by 
population average measurements or even by multiple-rounds of single-cell low-
plex measurements.  
As a first step in analyzing single-cell distributions in CycIF data, we 
performed k-means clustering and chose unperturbed cells. We started with k = 5 
clusters and used the cosine distance metric, which distinguishes marker 
combinations primarily by their orientation in signaling space. We then iteratively 
merged clusters in cases where projections along pairwise centroid lines were 
not bimodal. This procedure yielded k = 3 well-defined clusters that can be 
projected as single-cell densities into a plane defined by cluster centroids. These 
clusters appear to correspond to three distinct cell cycle states. Most populated 
cluster (77% of cells) was distinguished from the next-most populated cluster of 
cells (22%) by lower levels of pRb, PCNA, and higher levels of p27/Kip1, 
suggesting that the clusters correspond to non-proliferating and proliferating 
cells. A third, relatively disperse cluster (red, 1%) was distinguished by higher γ-
H2AX, p-Histone H3, and p-AuroraA/B/C staining, each of which is indicative of 
mitosis. A limitation of this analysis is, however, that a linear planar projection is 
unlikely to capture the full heterogeneity of the cells, and that no additional states 
or transitions of cell cycle progression were resolved by k-means. 
Graph-based trajectory reconstruction can be used as means to interpret 
high-dimensional data based on the inference of temporal order. It has been 
shown that cell-cycle trajectories can be reconstructed from fixed cell images 
(Kafri et al., 2013) and complex differentiation programs from CyTOF data 
(Bendall et al., 2014). The Wanderlust algorithm accomplishes this by connecting 
nearest neighbors among subsampled single-cell readouts as a means to place 
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them on single axis (Gut et al., 2015). When applied to CycIF data from 
unperturbed MCF10A cultures, the Wanderlust algorithm indeed reconstructed 
known cell cycle transitions, in support of antibody selectivity and the notion that 
CycIF data captures a rich set of biological information. We saw that on the 
Wanderlust axis, normalized DNA content (Hoechst 33342 staining) is low from 
6x104 to 12x104, at which point it rises steadily, concomitant with a rise in Rb 
phosphorylation. Between 6x104 and 12x104 the levels of the p21/Cip1 and 
p27/Kip1 CDKIs were high and Cyclin D1 levels increased rapidly. These 
trajectories recapitulated well-documented changes in cell cycle regulators 
whereby expression of Cyclin D1 in G0/G1 permits CDK2 to overcome p27/Kip1 
inhibition and mark it for degradation. This leads to activation of a switch that 
leads to Rb phosphorylation and thereby, licensing of DNA replication, and entry 
into S phase. Cyclin D1 concentration occurs in cells with 4N DNA followed by 
mitosis in cells with high PCNA levels, at which point the Wanderlust plot can be 
assumed to wrap over to the left. 
Multiplex imaging reveals that the exposure of cells to targeted anti-cancer 
drugs induces cell cycle states that are not found in normal cells and that these 
can be heterogeneous across the population. We and others and we have linked 
such heterogeneity among genetically identical cells to submaximal drug 
response and the perdurance of drug-resistant subpopulations potentially 
involved in residual disease. The t-SNE implementation viSNE yields a flat 
projection that better represents heterogeneity than conventional projection of k-
means clusters and has previously been shown to work well with CyTOF data 
(Amir el et al., 2013). The same data used to generate the Wanderlust plot were 
projected here using viSNE algorithm. The viSNE plots from p-RB and Ki-67 
stainings (both of which are markers of cell proliferation) occupy the territories 
opposite to the p21/Cip1 (negative cell cycle regulator). When viSNE was used to 
project data from untreated MCF10a and cells color-coded by Wanderlust index, 
we observed that the cell cycle precedes counter-clockwise through the 
projection. A “peninsula” in the edge of the viSNE space encompasses the Ki-67 
negative cells subset of non-cycling cells and likely corresponded to the 
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quiescent fraction of the MCF10A culture. As a control in contrast, merging four 
replicate sets from DMSO-treated cultures yielded a viSNE projection in which 
none of the replicates segregated. 
 To compare drug responses at a single-cell level we merged CycIF data 
from cells treated with each of the four different kinase inhibitors or with DMSO 
alone. The doses of drugs used here were selected to lie between GI50 and GI80.  
Projecting the data with viSNE yielded a landscape in which different drugs 
mapped to different regions of the space. For example the mTOR/PI3K drugs 
Torkinib and Dactolisib were distinct from the populated patch corresponding to 
treatment with the EGFR or MEK inhibitors Lapatinib and Selumetinib. This 
shows that the localization of cells in the viSNE projection reflects differences in 
drug response. These projections also demonstrated numerous subpopulations 
after drug treatment that fragmented landscapes. 
To interpret these viSNE clusters at the level of signaling, we color-coded 
data points in the same viSNE projection according to the relative intensity of 
each CycIF signal. Antibodies specific to different cell cycle proteins and 
phosphorylation states revealed multiple subpopulations distinguished by 
antigens commonly thought to exhibit similar regulation of biological processes. 
Specifically, antibodies against Ki-67 stained the largest number of cells whereas 
antibodies against PCNA and p-Rb labeled only distinct subpopulations within 
the Ki-67 domain. Because Cyclin D/CDK complexes promote Rb 
phosphorylation, the point in the cell cycle at which Cyclin D1 abundance is 
highest is usually thought to correspond to the point of maximal Rb 
phosphorylation. However, we found that cells with the highest Cyclin D1 
concentrations were p-Rb negative and exhibited strong p21/Cip1 and p53 
staining. This subpopulation likely corresponds to a non-proliferative state that 
has previously been described as an alternative mode of cell cycle exit (Chen et 
al., 2013).  
Consistent with our PCA of the traditional IF drug screen dataset, viSNE 
domains populated by cells treated with EGFR or MEK inhibitor (Lapatinib or 
Selumetinib) featured higher levels of p27/Kip1 (and also FOXO3a) than viSNE 
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domains corresponding to mTOR inhibition by Dactolisib or Torkinib. When we 
examined the distribution of p-ERK1/2 and p-S6, which function as signals 
downstream of all drugs in our panel but upstream of cell cycle regulators we 
found that viSNE domains corresponding to treatment of cells with Torkinib 
exhibited greatly reduced S6 phosphorylation at S235/236 and S240/244 but 
high p-ERK1/2 levels. This is in agreement with previous data showing that 
mTOR inhibition relieves ERK from negative feedback, albeit through an unclear 
mechanism (Albert et al., 2009; Carracedo et al., 2008). 
To explore the ability of viSNE to dissect drug responses in cell 
subpopulations in comparison with classic scatter plots, we gated on the cluster 
of Torkinib-treated cells that featured the highest p-Rb levels and examined the 
marginal distributions of the signaling proteins in this cluster. This analysis 
revealed strong Ki-67 and PCNA expression, low p21/Cip1 and p27/Kip1 
expressions and 2N DNA content indicative of S/G2-like cells that are still 
proliferating. We conclude that although most MCF10A cells arrest in the 
presence of Torkinib, a subset of cells escapes this effect, which may underlie 
the reduced Emax observed for Torkinib. More generally, the ability to isolate this 
subset suggests that our dataset is informative of abnormal cell cycle states that 
may potentially underlie resistance. 
 
Further research is required to test these ideas. However it is evident that 
the near-universal use of population average measurements to characterize drug 
response at cellular level is prone to missing important information. However, 
effective analysis of single-cell data involving drug-induced subpopulations and 
cell-cycle bifurcations will requires the development of new algorithms. Existing 
graph reconstruction methods such as Wanderlust and Wishbone are not yet 
fully able to fully deal with this complexity in the context of pharmacology. 
 
While multiplex single-cell imaging using methods such as CycIF are no 
more complicated than conventional IF, they are substantially cost-effective since 
they cut down on the amount of cell culture material and reveal connections 
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between molecular signals and phenotypes that cannot be discerned using 
population average methods or multiple rounds of low-plex measurement across 
many cell culture samples. Cell cycle progression, for example, can be directly 
inferred from such data using graph-based trajectory reconstruction. The image 
segmentation and analysis routines used in this thesis are intentionally simple 
ones and primarily yielding per-cell intensity data.  The addition of morphometric 
data (on cell shape or the organization of the cytoskeleton for example) will most 
certainly yield additional insight. I hope that the data in this thesis will motivate 
methodologies for analyzing or visualizing of high-dimensional single-cell data on 
normally growing and drug-treated cells.  
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5. SUMMARY 
 
The activities of small molecule anti-cancer drugs are commonly 
measured in cell-based assays as means to optimize drug properties, study 
biological processes such as cell growth and death, and identify factors that 
control drug sensitivity and resistance. Most of these assays involve 
measurement of a single parameter in drug-treated cells, commonly the number 
of viable cells. However, understanding the mechanisms of action of therapeutics 
requires characterizing drug-induced changes in intracellular states. This typically 
involves inhibition of oncogene signaling, changes in cell cycle distribution and 
induction of senescence or apoptosis. Near-universal use of conventional single-
parameter screening techniques used in drug discovery fail to systematically 
assess this complexity.  Thus, multiplex methods are required to collect drug 
dose-responses from multiple molecular signals and cellular phenotypes along a 
response pathway. Multiplex assays such as flow-based methods have the 
potential to provide data on many more features of drug-perturbed cells but are 
difficult to perform in high-throughput on adherent cells; bead-based immuno-
assays are expensive and provide only well-average data. In this thesis, we 
argue that high-content and high-throughput microscopy is ideal for this purpose 
as it not only combines aspects of phenotypic and target-centric approaches in 
cell populations, but also sheds light on the molecular details of drug-induced 
phenotypes at single-cell level. 
Analysis of phenotypic dose-response curves from 9 kinase inhibitors 
measured by high-throughput microscopy revealed systematic similarities and 
variations between different drugs. For example, EGFR-targeting drugs exhibited 
much steeper hill slope (HS) compared to drugs targeting MEK, AKT or mTOR. 
While all effective drugs had similar averaged maximal cytostatic effects 
(Emax~1.1), the accumulation of Cyclin-dependent kinase inhibitors (CDKIs) 
varied from one drug to the next. 
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Principal component analysis (PCA) on the measured molecular signals 
captured 90% of the variance in two principal components (PCs) indicating that 
the bulk signaling changes in response to all explored drugs can be understood 
within a plane spanned by two orthogonal axes of protein synthesis (p-4EBP1 
and p-S6) and cell cycle progression (p-CDK2, p27/Kip1). Interestingly, mTOR 
inhibition caused dose-dependent upregulation of ERK1/2 phosphorylation that 
may be counter-therapeutic. Furthermore, we investigated the importance of 
MAPK signaling dynamics in a panel of immortalized and cancer cell lines in 
response to a dual EGFR/HER tyrosine kinase inhibitor (Lapatinib). Averaged 
ERK1/2 phosphorylation response curve at intermediate time points was highly 
correlated with the late phenotypic response (R2=0.96) and the transient p-
ERK1/2 inhibition was associated with translocation of EGFR to plasma 
membrane and recovery of EGFR phosphorylation. Combination of two EGFR 
inhibitors led to sustained inhibition of EGFR/MEK/ERK signaling pathway and 
thereby the inhibition of proliferation measured by Rb phosphorylation. 
Even though averaged measurements of drug response is clearly useful in 
investigating how cells at the population level behave in response to drugs, 
single cell profiling is increasingly recognized as means to understand natural 
and induced changes in cellular physiology. Progress has been particularly rapid 
in the case of highly multiplexed flow-based methods but in contrast, microscopy-
based profiling approaches have lagged behind both with respect to the 
development of easily implemented assays and computational analysis 
frameworks. 
We monitored the response to 4 kinase inhibitors targeting immediate-
early signaling pathways in the widely used, non-transformed mammary epithelial 
cell line using a novel “cyclic immunofluorescence” method (CycIF) capable of 
imaging up to 30 channels and analyzed the data using existing tools like k-
means clustering, viSNE and Wanderlust algorithms. We were able to 
reconstitute different stages of cell cycle from Wanderlust trajectory. Using viSNE 
algorithm, we showed that different drugs lead to emergence of distinct 
subpopulations. In particular, response to mTOR targeting drugs was associated 
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with resistance of a subpopulation in S/G2 cell cycle phase that was highly 
enriched with markers of proliferation. Thus, highly multiplexed single-cell 
imaging reveals valuable insight into mechanisms of drug action and cell-to-cell 
variability in drug response. 
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6. ZUSAMMENFASSUNG 
 
Die Wirkung von niedermolekularen Krebsmedikamenten wird normalerweise 
mittels zell-basierten Analysen getestet, um die Wirksamkeit zu optimieren, 
Erkenntnisse über Zellwachstum und -tod zu gewinnen, sowie Faktoren zu 
identifizieren, die Resistenz und Sensitivität beeinflussen. 
Viele dieser Methoden umfassen die Messung eines einzelnen Parameters der 
medikamentös-behandelten Zellen, meist die Anzahl lebender Zellen. Um die 
Wirkmechanismen von Therapeutika zu verstehen, müssen die 
arzneimittelbedingten Veränderungen auch hinsichtlich des intrazellulären 
Zustandes charakterisiert werden. Dies beinhaltet üblicherweise die Inhibition der 
Onkogen-Signalwege, Veränderungen in dem Zellzyklus und Induktion von 
Seneszenz oder Apoptose. Naheliegende konventionelle Einzelparameter 
Screening Techniken, wie sie in der Arzneimittelforschung genutzt werden, sind 
nicht im Stande diese Komplexität methodisch zu bewerten. Deshalb sind 
Multiplex Methoden erforderlich, um den Dosis-Wirkungs-Verlauf von multiplen 
molekularen Signalen und zellulären Phänotypen zu erfassen. Multiplex 
Analysen, wie durchfluss-basierte Methoden, haben das Potential Daten zu 
vielen Eigenschaften von medikamentös behandelten Zellen zu liefern, es ist 
aber schwierig dieses im Hochdurchsatz mit adhärenten Zellen durchzuführen. 
Bead-basierte Immuntests sind teuer und liefern nur Durchschnittswerte je Well. 
In dieser These behaupten wir, dass hochauflösende und Hochdurchsatz-
Mikroskopie für diesen Verwendungszweck ideal ist, da nicht nur Aspekte wie  
Phänotyp- und Ziel-basierende Ansätze, sondern auch molekulare Details der 
medikamentös-induzierten Phänotypen der einzelnen Zellen einbezogen werden 
können. 
 
Die Analyse der phänotypischen Dosis-Wirkungs-Kurven von neun Kinase-
Inhibitoren, gemessen mittels Hochdurchsatz-Mikroskopie, zeigt systematische 
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Parallelen, aber auch Variationen zwischen den verschiedenen Medikamenten. 
Zum Beispiel zeigen EGFR-modifizierte Medikamente einen steileren Hill-Anstieg 
im Vergleich zu Medikamenten, die MEK, AKT oder mTOR modifizieren. 
Während alle wirksamen Medikamente vergleichbare durchschnittliche maximale 
zytostatische Effekte (Emax~1.1) hatten, variierte die Zunahme von Cyclin-
abhängigen Kinase Inhibitoren (CDKIs) der einzelnen Medikamente. 
 
Die Hauptkomponentenanalyse (PCA) der gemessenen molekularen Signale 
erfasst 90% der Varianz von zwei wesentlichen Bestandteilen (PCs), daraus 
ergibt sich, dass ein Großteil der veränderten Signale im Zusammenhang mit 
allen erforschten Medikamenten mittels einer zweidimensionalen Fläche 
zwischen orthogonalen Axen für Protein-Synthese (p-4EBP1 und p-S6) und 
Zellzyklus-Verlauf (p-CDK2, p27/Kip1) beschreiben werden kann. 
Interessanterweise verursacht die Inhibition von mTOR einen dosisabhängigen 
Anstieg der Phosphorylation von ERK1/2, der die Wirkung verringern könnte. 
Außerdem untersuchten wir die Bedeutung von MAPK-Signalwegen in einem 
“Panel” von immortalisierten und Krebszelllinien in Reaktion auf einen doppelten 
EGFR/HER Tyrosin-Kinase-Inhibitor (Lapatinib). Im Durchschnitt gab es eine 
hohe Korrelation des Verlaufs der ERK1/2-Phophorylation mit der 
phänotypischen Reaktion (R2=0.96), und die transiente Inhibition von p-ERK1/2 
wurde mit der Translokation von EGFR zur Plasmamembran und 
Wiederherstellung der EGFR Phosphorylation in Zusammenhang gebracht. Die 
Kombination von zwei EGFR Inhibitoren führte zu kontinuierlicher Inhibition des 
EGFR/MEK/ERK Signalwegs und in der Folge zur Inhibition der Proliferation, 
gemessen anhand der Phosphorylierung von Rb. 
Obwohl die durchschnittlichen Messungen der Dosiswirkung zweifellos nützlich 
sind, um das Verhalten der gesamten Zellenpopulation auf die entsprechenden 
Medikamente zu erforschen, wird die Einzel-Zell-Analyse zunehmend als 
Möglichkeit für die Erforschung von natürlichen und induzierten Veränderungen 
in der Zellphysiologie anerkannt. Die Entwicklung war besonders schnell im Fall 
von Hochdurchsatz-durchfluss-basierten Methoden, demgegenüber war das 
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Entstehen von Mikroskopie-basiertem “Profiling” verzögert wegen der 
Entwicklung von einfach umzusetzenden Analysen sowie von rechnerisch 
analytischen Systemen. 
Wir überwachten die Reaktion auf vier Kinase-Inhibitoren, die auf den frühen 
Signalweg wirken. Wir verwendeten dafür die häufig genutzten, nicht 
umgewandelten, mamillären epithelialen Zellinien und dazu eine neuartige 
“zyklische Immunfluoreszenz” Methode (CycIF), die fähig ist bis zu 30 Kanäle 
gleichzeitig abzubilden. Zur Datenanalyse wurden bereits bestehende Hilfsmittel 
wie k-means-Algorithmus, viSNE- und Wanderlust-Algorithmus verwendet. Wir 
waren in der Lage verschiedene Abschnitte des Zellzyklus mit der Wanderlust-
Zeitschiene darzustellen. Mittels viSNE-Algorithmus konnten wir zeigen, dass 
verschiedene Medikamente zur Entstehung von eigenständigen Subpopulationen 
führen. Im Besonderen konnte die Reaktion von Medikamenten die auf mTOR 
wirken, mit einer Resistenz einer Subpopulation im S/G2 Zellzyklus in 
Zusammenhang gebracht werden. In dieser Subpopulation waren 
Proliferationsmarker sehr stark angereichert. Folglich offenbart das “Multiplex-
Single-Cell-Imaging” nützliche Einblicke in die Wirkmechanismen von 
Medikamenten und Zell-zu-Zell-Variabilität. 
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